

Reference Section E
morbidity & hospitalization



table e.1 · 389
first admissions: esrd patients
per 1,000 patient years, period prevalent patients, 2000, by primary diagnosis & age

table e.2 · 390
first admissions: dialysis patients
per 1,000 patient years, period prevalent patients, 2000, by primary diagnosis & age

table e.3 · 391
first admissions: hemodialysis patients
per 1,000 patient years, period prevalent patients, 2000, by primary diagnosis & age

table e.4 · 392
first admissions: capd/ccpd patients
per 1,000 patient years, period prevalent patients, 2000, by primary diagnosis & age

table e.5 · 393
first admissions: transplant patients
per 1,000 patient years, period prevalent patients, 2000, by primary diagnosis & age

table e.6 · 394
first admission standardized hospitalization ratios for selected years
period prevalent dialysis patients, by state

table e.7 · 395
total admissions: esrd patients, 2000
per 1,000 patient years, period prevalent patients, by primary diagnosis & age; grouped by gender & race

table e.8 · 396
total admissions: esrd patients, 1998-2000 combined
per 1,000 patient years, period prevalent patients, by primary diagnosis & age; grouped by gender & race

table e.9 · 397
total admissions: dialysis patients, 2000
per 1,000 patient years, period prevalent patients, by primary diagnosis & age; grouped by gender & race

table e.10 · 398
total admissions: dialysis patients, 1998-2000 combined
per 1,000 patient years, period prevalent patients, by primary diagnosis & age; grouped by gender & race

table e.11 · 399
total admissions: hemodialysis patients, 2000
per 1,000 patient years, period prevalent patients, by primary diagnosis & age; grouped by gender & race

table e.12 · 400
total admissions: hemodialysis patients, 1998-2000 combined
per 1,000 patient years, period prevalent patients, by primary diagnosis & age; grouped by gender & race

table e.13 · 401
total admissions: capd/ccpd patients, 2000
per 1,000 patient years, period prevalent patients, by primary diagnosis & age; grouped by gender & race

table e.14 · 402
total admissions: capd/ccpd patients, 1998-2000 combined
per 1,000 patient years, period prevalent patients, by primary diagnosis & age; grouped by gender & race

table e.15 · 403
total admissions: transplant patients, 2000
per 1,000 patient years, period prevalent patients, by primary diagnosis & age; grouped by gender & race

table e.16 · 404
total admissions: transplant patients, 1998-2000 combined
per 1,000 patient years, period prevalent patients, by primary diagnosis & age; grouped by gender & race

table e.17 · 405
hospital days: esrd patients, 2000
per patient year, period prevalent patients, by primary diagnosis & age; grouped by gender & race

table e.18 · 406
hospital days: esrd patients, 1998-2000 combined
per patient year, period prevalent patients, by primary diagnosis & age; grouped by gender & race

table e.19 · 407
hospital days: dialysis patients, 2000
per patient year, period prevalent patients, by primary diagnosis & age; grouped by gender & race

table e.20 · 408
hospital days: dialysis patients, 1998-2000 combined
per patient year, period prevalent patients, by primary diagnosis & age; grouped by gender & race

table e.21 · 409
hospital days: hemodialysis patients, 2000
per patient year, period prevalent patients, by primary diagnosis & age; grouped by gender & race

table e.22 · 410
hospital days: hemodialysis patients, 1998-2000 combined
per patient year, period prevalent patients, by primary diagnosis & age; grouped by gender & race

table e.23 · 411
hospital days: capd/ccpd patients, 2000
per patient year, period prevalent patients, by primary diagnosis & age; grouped by gender & race

table e.24 · 412
hospital days: capd/ccpd patients, 1998-2000 combined
per patient year, period prevalent patients, by primary diagnosis & age; grouped by gender & race

table e.25 · 413
hospital days: transplant patients, 2000
per patient year, period prevalent patients, by primary diagnosis & age; grouped by gender & race

table e.26 · 414
hospital days: transplant patients, 1998-2000 combined
per patient year, period prevalent patients, by primary diagnosis & age; grouped by gender & race

table e.27 · 415
total hospital discharges: by general diagnostic related group
period prevalent patients, 1998-2000 combined, by primary diagnosis & age; grouped by gender & race

Table E.1

First Admissions: ESRD Patients

per 1,000 patient years, period prevalent patients, 2000, by primary diagnosis & age

DIABETES	Male					Female					All				
	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All
0-19	1,420	1,642	1,645	1,370	1,553	1,755	2,053	1,954	1,556	1,927	1,726	2,014	1,799	1,463	1,892
20-29	1,309	1,419	1,375	1,130	1,346	1,475	1,791	1,603	1,267	1,600	1,391	1,625	1,537	1,213	1,478
30-39	1,268	1,377	1,261	996	1,288	1,309	1,535	1,514	1,122	1,381	1,283	1,454	1,375	1,060	1,326
40-49	1,230	1,289	1,234	961	1,241	1,441	1,486	1,408	1,064	1,447	1,307	1,381	1,308	1,003	1,324
50-59	1,255	1,202	1,188	1,005	1,224	1,498	1,438	1,342	1,161	1,453	1,357	1,325	1,263	1,068	1,330
60-64	1,379	1,204	1,234	1,056	1,295	1,568	1,362	1,397	1,045	1,445	1,471	1,295	1,313	1,050	1,374
65-69	1,430	1,242	1,394	992	1,346	1,553	1,384	1,336	1,020	1,452	1,494	1,331	1,356	1,007	1,406
70-79	1,502	1,316	1,322	1,052	1,432	1,606	1,519	1,356	1,014	1,539	1,557	1,452	1,344	1,029	1,494
80+	1,669	1,541	1,462	1,116	1,605	1,781	1,646	1,456	1,058	1,682	1,728	1,615	1,458	1,082	1,650
All	1,377	1,263	1,255	1,024	1,324	1,554	1,459	1,368	1,051	1,489	1,460	1,378	1,317	1,039	1,409
HYPERTENSION															
0-19	773	842	952	685	834	937	1,091	1,157	799	1,033	885	976	989	769	947
20-29	658	733	855	586	710	871	958	1,034	683	927	733	802	943	611	780
30-39	771	848	852	627	825	886	992	973	662	957	811	894	880	638	868
40-49	813	878	905	600	858	929	1,045	985	690	1,006	849	929	933	638	904
50-59	965	892	980	704	908	1,098	1,053	1,061	716	1,052	1,010	950	1,009	709	959
60-64	1,106	989	1,051	783	1,025	1,297	1,071	1,189	799	1,136	1,181	1,026	1,118	788	1,072
65-69	1,184	1,054	1,191	758	1,112	1,368	1,227	1,267	783	1,263	1,256	1,141	1,231	771	1,181
70-79	1,292	1,193	1,300	881	1,251	1,503	1,341	1,310	781	1,399	1,375	1,278	1,306	829	1,320
80+	1,419	1,441	1,476	998	1,406	1,585	1,578	1,437	875	1,550	1,489	1,527	1,448	935	1,475
All	1,191	961	1,027	787	1,059	1,396	1,187	1,184	774	1,256	1,270	1,056	1,098	781	1,140
GLOMERULONEPHRITIS															
0-19	736	930	844	679	803	842	1,170	1,004	751	941	792	1,040	938	709	872
20-29	635	698	731	576	660	861	960	855	651	888	722	804	794	609	751
30-39	603	731	756	563	653	765	905	861	606	819	661	803	810	580	717
40-49	715	889	750	560	776	787	948	893	594	828	740	910	801	579	795
50-59	796	856	870	648	810	918	985	984	659	920	842	904	915	653	853
60-64	910	964	884	720	914	1,036	1,048	1,029	751	1,026	956	1,003	946	732	959
65-69	1,048	1,031	983	756	1,034	1,098	1,141	1,014	747	1,088	1,068	1,083	998	751	1,058
70-79	1,124	1,060	1,070	774	1,100	1,329	1,229	1,119	775	1,270	1,198	1,145	1,095	775	1,166
80+	1,329	1,430	1,233	944	1,324	1,450	1,411	1,278	884	1,407	1,376	1,420	1,261	910	1,358
All	862	851	827	636	846	1,001	1,003	944	666	976	914	913	880	651	897
OTHER															
0-19	758	1,062	1,057	786	841	843	1,292	1,260	936	957	794	1,153	1,142	857	889
20-29	687	914	944	673	758	976	1,173	1,117	818	1,041	810	1,046	1,053	752	889
30-39	727	1,013	921	631	830	901	1,120	1,095	789	986	806	1,065	1,015	708	903
40-49	762	959	967	679	843	901	1,091	1,005	748	970	822	1,016	983	720	899
50-59	859	918	962	729	877	963	1,086	1,093	767	995	910	994	1,026	750	933
60-64	956	1,114	1,089	782	997	1,095	1,177	1,109	820	1,110	1,023	1,147	1,098	804	1,054
65-69	1,092	1,071	1,173	818	1,079	1,236	1,227	1,219	803	1,218	1,158	1,151	1,197	810	1,145
70-79	1,196	1,175	1,155	809	1,181	1,346	1,380	1,213	866	1,333	1,260	1,278	1,184	840	1,249
80+	1,374	1,358	1,308	910	1,359	1,545	1,599	1,400	852	1,527	1,443	1,479	1,349	880	1,430
All	970	1,015	1,028	741	977	1,109	1,179	1,123	803	1,118	1,032	1,093	1,074	775	1,042
ALL															
0-19	754	1,010	997	734	831	847	1,240	1,160	856	959	796	1,108	1,070	790	888
20-29	712	800	838	620	747	981	1,108	1,047	749	1,024	822	929	954	679	863
30-39	847	908	941	635	867	969	1,087	1,093	749	1,015	895	981	1,012	683	926
40-49	911	959	1,032	676	929	1,047	1,140	1,185	717	1,075	962	1,026	1,093	697	985
50-59	1,034	985	1,116	816	1,006	1,197	1,217	1,274	850	1,195	1,103	1,085	1,190	832	1,087
60-64	1,168	1,093	1,180	888	1,129	1,359	1,237	1,333	933	1,286	1,255	1,169	1,253	910	1,205
65-69	1,250	1,135	1,312	887	1,199	1,411	1,310	1,307	909	1,345	1,326	1,234	1,309	899	1,274
70-79	1,315	1,228	1,275	918	1,280	1,500	1,428	1,325	899	1,444	1,398	1,349	1,306	907	1,362
80+	1,441	1,451	1,401	1,013	1,425	1,612	1,598	1,428	934	1,573	1,515	1,544	1,419	970	1,497
All	1,136	1,033	1,131	816	1,087	1,323	1,274	1,270	852	1,281	1,217	1,150	1,203	835	1,175

Includes all patients who have reached day 91 of ESRD by December 31 of each calendar year.
Patient age is determined on January 1 of each calendar year.

Table E.2
First Admissions: Dialysis Patients
per 1,000 patient years, period prevalent patients, 2000, by primary diagnosis & age

DIABETES	Male					Female					All				
	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All
0-19	1,822	1,857	1,808	1,613	1,842	2,309	2,310	2,158	1,823	2,309	1,924	2,267	1,983	1,718	2,241
20-29	1,499	1,491	1,378	1,204	1,489	1,724	1,941	1,607	1,328	1,805	1,613	1,734	1,540	1,285	1,657
30-39	1,527	1,458	1,305	1,095	1,493	1,557	1,630	1,545	1,216	1,575	1,538	1,544	1,411	1,153	1,526
40-49	1,424	1,314	1,268	1,049	1,368	1,673	1,488	1,468	1,114	1,563	1,516	1,397	1,357	1,076	1,449
50-59	1,342	1,221	1,217	1,031	1,278	1,577	1,460	1,355	1,187	1,498	1,443	1,346	1,286	1,094	1,382
60-64	1,425	1,216	1,266	1,101	1,325	1,597	1,373	1,414	1,077	1,465	1,511	1,308	1,340	1,088	1,401
65-69	1,454	1,247	1,387	999	1,363	1,560	1,381	1,337	1,018	1,454	1,511	1,332	1,353	1,009	1,415
70-79	1,507	1,317	1,314	1,047	1,435	1,605	1,516	1,354	1,010	1,537	1,559	1,451	1,340	1,024	1,495
80+	1,664	1,536	1,453	1,106	1,600	1,776	1,642	1,445	1,042	1,677	1,723	1,611	1,448	1,069	1,645
All	1,457	1,278	1,278	1,047	1,376	1,607	1,467	1,380	1,058	1,518	1,530	1,390	1,334	1,053	1,452
HYPERTENSION															
0-19	897	881	959	747	887	1,112	1,133	1,171	874	1,127	1,022	1,029	959	787	1,020
20-29	702	695	800	582	693	886	922	970	677	906	769	767	888	611	763
30-39	817	842	822	649	833	991	999	966	694	991	876	892	857	662	884
40-49	850	871	912	632	862	1,018	1,064	978	742	1,045	901	930	937	678	919
50-59	1,049	901	963	720	935	1,162	1,056	1,054	743	1,072	1,088	958	996	730	984
60-64	1,159	984	1,049	794	1,039	1,358	1,085	1,195	811	1,160	1,237	1,030	1,122	799	1,091
65-69	1,208	1,046	1,186	776	1,120	1,392	1,234	1,265	796	1,277	1,280	1,142	1,228	787	1,192
70-79	1,300	1,193	1,298	889	1,256	1,508	1,346	1,314	781	1,403	1,382	1,282	1,308	832	1,325
80+	1,419	1,443	1,499	1,008	1,407	1,585	1,578	1,464	883	1,550	1,489	1,528	1,474	944	1,476
All	1,233	965	1,035	818	1,082	1,437	1,201	1,193	794	1,281	1,312	1,066	1,110	807	1,164
GLOMERULONEPHRITIS															
0-19	857	920	861	718	875	1,016	1,174	1,045	805	1,072	940	1,049	949	758	976
20-29	713	664	699	559	679	912	939	811	619	900	794	776	756	586	771
30-39	659	735	738	559	688	896	906	868	636	888	743	807	807	584	765
40-49	804	905	768	583	839	876	978	898	616	893	830	931	812	601	859
50-59	879	862	889	681	863	1,052	994	1,013	673	998	946	911	939	677	916
60-64	1,019	973	897	747	989	1,110	1,055	1,044	772	1,073	1,054	1,012	962	756	1,024
65-69	1,091	1,035	1,010	770	1,066	1,151	1,135	1,037	745	1,121	1,116	1,083	1,021	756	1,091
70-79	1,134	1,058	1,100	783	1,108	1,342	1,230	1,146	768	1,278	1,210	1,145	1,124	776	1,175
80+	1,336	1,442	1,289	956	1,332	1,457	1,423	1,333	890	1,415	1,383	1,432	1,316	919	1,366
All	958	861	844	659	908	1,113	1,016	960	687	1,045	1,017	925	896	673	962
OTHER															
0-19	1,053	1,212	1,156	958	1,107	1,140	1,481	1,441	1,099	1,258	1,091	1,330	1,180	1,027	1,173
20-29	763	913	951	728	819	1,116	1,213	1,140	887	1,144	910	1,059	1,073	816	967
30-39	800	1,051	960	694	905	1,035	1,179	1,154	876	1,097	903	1,111	1,066	774	992
40-49	868	986	996	751	923	1,044	1,123	1,084	858	1,074	943	1,044	1,031	808	988
50-59	950	933	973	736	936	1,107	1,120	1,160	799	1,099	1,026	1,017	1,057	770	1,013
60-64	1,050	1,134	1,104	815	1,070	1,213	1,214	1,159	857	1,199	1,129	1,176	1,130	840	1,135
65-69	1,136	1,067	1,163	826	1,108	1,307	1,229	1,235	836	1,265	1,213	1,151	1,203	831	1,182
70-79	1,202	1,174	1,153	809	1,185	1,355	1,385	1,225	864	1,340	1,268	1,280	1,190	838	1,254
80+	1,373	1,345	1,311	909	1,356	1,544	1,594	1,417	855	1,525	1,442	1,470	1,358	881	1,427
All	1,065	1,036	1,050	778	1,047	1,235	1,217	1,173	853	1,212	1,140	1,121	1,109	817	1,122
ALL															
0-19	1,000	1,090	1,059	824	1,029	1,098	1,339	1,149	946	1,190	1,045	1,209	1,074	882	1,104
20-29	790	779	828	627	778	1,088	1,113	1,053	763	1,081	913	918	956	692	905
30-39	955	922	961	669	928	1,122	1,116	1,123	824	1,109	1,019	1,001	1,038	727	999
40-49	1,035	967	1,066	737	990	1,205	1,165	1,250	782	1,165	1,099	1,040	1,141	759	1,056
50-59	1,135	999	1,140	852	1,059	1,326	1,238	1,298	894	1,265	1,216	1,103	1,215	871	1,148
60-64	1,247	1,100	1,205	925	1,172	1,435	1,253	1,352	971	1,328	1,335	1,181	1,278	948	1,250
65-69	1,288	1,134	1,309	900	1,220	1,446	1,312	1,313	916	1,363	1,363	1,235	1,312	908	1,294
70-79	1,323	1,228	1,272	920	1,285	1,505	1,429	1,326	896	1,447	1,405	1,351	1,305	907	1,366
80+	1,441	1,449	1,407	1,016	1,425	1,611	1,597	1,437	933	1,572	1,515	1,542	1,426	971	1,497
All	1,224	1,047	1,157	855	1,141	1,417	1,294	1,295	886	1,338	1,308	1,168	1,229	871	1,232

Includes all patients who have reached day 91 of ESRD by December 31 of each calendar year. Patient age is determined on January 1 of each calendar year.

Table E.3

First Admissions: Hemodialysis Patients

per 1,000 patient years, period prevalent patients, 2000, by primary diagnosis & age

DIABETES	Male					Female					All				
	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All
0-19	1,776	1,781	1,771	1,534	1,778	2,323	2,267	2,170	1,779	2,266	1,781	2,120	1,970	1,657	2,063
20-29	1,497	1,479	1,382	1,176	1,482	1,834	1,951	1,626	1,308	1,865	1,649	1,728	1,575	1,262	1,674
30-39	1,534	1,497	1,337	1,070	1,506	1,629	1,618	1,554	1,218	1,608	1,566	1,557	1,439	1,138	1,546
40-49	1,444	1,297	1,260	1,041	1,369	1,698	1,468	1,442	1,122	1,558	1,536	1,379	1,340	1,073	1,447
50-59	1,335	1,210	1,200	1,002	1,266	1,558	1,449	1,334	1,184	1,483	1,431	1,335	1,266	1,075	1,369
60-64	1,411	1,208	1,261	1,088	1,310	1,587	1,360	1,410	1,095	1,452	1,500	1,297	1,336	1,092	1,387
65-69	1,449	1,234	1,411	1,009	1,353	1,555	1,380	1,351	1,016	1,451	1,506	1,326	1,371	1,012	1,410
70-79	1,502	1,320	1,307	1,052	1,431	1,603	1,505	1,343	995	1,530	1,556	1,445	1,330	1,016	1,489
80+	1,660	1,526	1,450	1,116	1,594	1,768	1,647	1,431	1,027	1,673	1,717	1,611	1,438	1,064	1,641
All	1,455	1,271	1,273	1,042	1,370	1,605	1,457	1,371	1,052	1,510	1,529	1,382	1,327	1,047	1,445
HYPERTENSION															
0-19	863	826	932	711	840	1,149	1,092	1,190	863	1,098	1,139	984	932	862	994
20-29	698	670	792	570	674	946	897	1,008	687	906	781	737	897	599	744
30-39	804	840	817	637	829	1,024	999	1,017	692	998	874	889	848	653	882
40-49	839	866	918	626	858	1,077	1,079	989	785	1,070	908	928	942	687	920
50-59	1,056	895	949	731	929	1,186	1,051	1,070	751	1,074	1,100	950	992	739	980
60-64	1,166	977	1,028	791	1,032	1,387	1,077	1,209	861	1,159	1,251	1,022	1,120	812	1,086
65-69	1,208	1,041	1,177	756	1,114	1,432	1,222	1,282	808	1,283	1,295	1,133	1,236	783	1,191
70-79	1,302	1,191	1,306	904	1,257	1,522	1,345	1,317	771	1,407	1,389	1,280	1,313	832	1,327
80+	1,431	1,434	1,486	1,014	1,415	1,596	1,586	1,446	869	1,559	1,501	1,529	1,457	939	1,484
All	1,242	962	1,032	828	1,081	1,467	1,207	1,216	798	1,295	1,329	1,066	1,118	814	1,169
GLOMERULONEPHRITIS															
0-19	844	882	860	712	859	1,043	1,122	1,069	816	1,064	935	1,002	861	786	960
20-29	702	646	704	569	666	904	903	878	648	884	779	747	777	604	751
30-39	655	728	748	566	685	924	915	916	667	907	741	801	820	599	764
40-49	804	913	778	606	846	905	990	955	654	921	838	938	821	630	872
50-59	877	856	918	714	862	1,071	980	1,057	712	1,007	949	901	972	713	916
60-64	1,036	964	917	773	998	1,149	1,078	1,076	802	1,103	1,078	1,016	996	785	1,040
65-69	1,097	1,029	1,017	786	1,068	1,163	1,136	1,048	753	1,126	1,125	1,079	1,031	765	1,094
70-79	1,134	1,056	1,101	805	1,107	1,368	1,237	1,162	802	1,299	1,219	1,147	1,133	804	1,183
80+	1,334	1,469	1,299	993	1,333	1,462	1,428	1,336	916	1,421	1,384	1,447	1,322	950	1,370
All	962	859	859	685	910	1,150	1,022	1,026	728	1,070	1,031	923	926	705	972
OTHER															
0-19	1,057	1,153	1,139	916	1,094	1,248	1,464	1,461	1,074	1,328	1,132	1,285	1,139	1,037	1,190
20-29	763	915	961	712	820	1,163	1,245	1,218	914	1,187	918	1,068	1,124	815	977
30-39	795	1,045	979	675	902	1,082	1,176	1,209	877	1,122	912	1,104	1,099	760	997
40-49	866	987	989	763	924	1,061	1,132	1,109	894	1,089	945	1,045	1,029	830	991
50-59	954	920	960	734	933	1,135	1,130	1,168	814	1,119	1,039	1,011	1,056	777	1,018
60-64	1,062	1,138	1,104	832	1,080	1,237	1,212	1,171	870	1,212	1,144	1,177	1,135	854	1,146
65-69	1,151	1,062	1,163	819	1,116	1,342	1,222	1,209	849	1,282	1,237	1,146	1,189	834	1,194
70-79	1,206	1,171	1,134	819	1,188	1,378	1,373	1,202	893	1,357	1,281	1,273	1,167	857	1,264
80+	1,363	1,345	1,299	922	1,348	1,534	1,594	1,396	847	1,517	1,432	1,469	1,345	882	1,420
All	1,071	1,033	1,047	780	1,050	1,271	1,224	1,193	869	1,238	1,157	1,120	1,114	826	1,133
ALL															
0-19	999	1,028	1,066	781	1,010	1,180	1,277	1,472	919	1,213	1,075	1,146	1,066	882	1,101
20-29	785	763	811	629	768	1,116	1,105	1,137	789	1,093	912	898	985	703	896
30-39	945	919	960	672	922	1,165	1,119	1,204	844	1,129	1,023	997	1,064	735	999
40-49	1,036	964	1,062	753	988	1,238	1,177	1,277	829	1,188	1,108	1,040	1,142	788	1,060
50-59	1,136	991	1,130	855	1,053	1,341	1,237	1,287	924	1,271	1,222	1,097	1,204	886	1,146
60-64	1,247	1,094	1,204	927	1,166	1,448	1,248	1,353	992	1,329	1,341	1,175	1,278	959	1,247
65-69	1,292	1,127	1,327	900	1,217	1,463	1,307	1,325	918	1,368	1,374	1,230	1,325	910	1,296
70-79	1,324	1,228	1,265	932	1,286	1,516	1,423	1,318	895	1,449	1,411	1,347	1,298	911	1,369
80+	1,443	1,443	1,405	1,028	1,427	1,614	1,603	1,422	924	1,574	1,518	1,544	1,416	971	1,499
All	1,230	1,045	1,157	867	1,141	1,442	1,299	1,307	901	1,353	1,322	1,168	1,235	884	1,239

Includes all patients who have reached day 91 of ESRD by December 31 of each calendar year.
Patient age is determined on January 1 of each calendar year.

Table E.4
First Admissions: CAPD/CCPD Patients
per 1,000 patient years, period prevalent patients, 2000, by primary diagnosis & age

DIABETES	Male					Female					All				
	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All
0-19	1,902	2,029	2,010	1,932	1,968	2,170	2,429	2,242	2,141	2,423	2,160	2,428	2,126	2,036	2,421
20-29	1,451	1,523	1,498	1,384	1,472	1,650	1,816	1,665	1,528	1,691	1,587	1,719	1,575	1,415	1,619
30-39	1,359	1,402	1,370	1,217	1,367	1,538	1,666	1,516	1,338	1,566	1,442	1,539	1,420	1,304	1,462
40-49	1,341	1,361	1,320	1,128	1,341	1,512	1,611	1,456	1,235	1,524	1,412	1,487	1,389	1,197	1,422
50-59	1,416	1,415	1,363	1,119	1,405	1,591	1,668	1,497	1,221	1,600	1,489	1,562	1,434	1,166	1,496
60-64	1,470	1,445	1,382	1,091	1,451	1,646	1,696	1,512	1,186	1,626	1,551	1,595	1,448	1,155	1,539
65-69	1,455	1,406	1,336	1,014	1,429	1,622	1,645	1,456	1,098	1,576	1,530	1,561	1,410	1,074	1,504
70-79	1,516	1,441	1,359	992	1,482	1,683	1,679	1,475	1,069	1,660	1,589	1,587	1,419	1,021	1,564
80+	1,628	1,523	1,426	1,000	1,597	1,801	1,767	1,542	1,075	1,725	1,700	1,718	1,542	1,049	1,658
All	1,440	1,413	1,359	1,053	1,422	1,614	1,669	1,488	1,149	1,603	1,517	1,564	1,427	1,109	1,509
HYPERTENSION															
0-19	973	1,115	1,180	941	1,012	1,042	1,252	1,236	978	1,153	996	1,188	1,208	943	1,067
20-29	795	896	942	722	835	848	1,002	982	748	922	819	948	968	731	875
30-39	796	883	922	679	848	846	984	958	701	931	819	928	942	688	885
40-49	841	917	951	674	884	890	1,019	984	692	966	860	963	976	684	921
50-59	951	1,021	1,051	715	976	1,003	1,129	1,083	733	1,065	970	1,076	1,062	725	1,017
60-64	1,057	1,116	1,141	747	1,066	1,110	1,229	1,171	762	1,153	1,081	1,189	1,150	756	1,112
65-69	1,120	1,162	1,180	743	1,123	1,172	1,276	1,207	755	1,168	1,143	1,223	1,187	752	1,145
70-79	1,248	1,275	1,285	778	1,229	1,301	1,394	1,310	787	1,298	1,269	1,334	1,298	781	1,257
80+	1,436	1,442	1,444	840	1,409	1,490	1,571	1,465	846	1,462	1,456	1,542	1,454	843	1,431
All	1,130	1,002	1,077	738	1,068	1,174	1,132	1,057	747	1,131	1,148	1,067	1,067	743	1,096
GLOMERULONEPHRITIS															
0-19	940	1,051	881	708	937	1,021	1,197	936	746	1,065	988	1,131	912	709	1,007
20-29	758	834	694	536	767	820	946	734	563	844	790	892	724	549	807
30-39	750	811	671	498	738	808	917	707	521	836	780	881	700	505	792
40-49	782	832	683	488	777	840	937	717	508	824	811	890	709	502	803
50-59	874	914	745	511	852	934	1,026	779	531	911	902	970	761	522	881
60-64	958	987	799	527	921	1,021	1,103	832	545	1,046	986	1,077	799	528	983
65-69	1,002	1,015	816	517	992	1,064	1,130	846	533	1,073	1,029	1,086	816	522	1,029
70-79	1,103	1,099	877	535	1,088	1,166	1,219	906	549	1,146	1,126	1,167	906	542	1,110
80+	1,253	1,227	973	570	1,247	1,319	1,356	1,001	583	1,290	1,276	1,280	998	580	1,262
All	922	877	730	518	881	951	986	727	525	924	935	940	728	522	902
OTHER															
0-19	1,016	1,277	1,310	1,034	1,091	1,097	1,447	1,383	1,085	1,195	1,058	1,362	1,383	1,052	1,144
20-29	816	1,009	1,028	780	886	878	1,139	1,081	815	978	851	1,089	1,065	807	940
30-39	805	979	990	722	860	862	1,100	1,037	752	947	839	1,055	1,017	737	913
40-49	836	1,000	1,005	705	890	892	1,120	1,049	731	980	869	1,076	1,041	720	944
50-59	930	1,094	1,092	736	960	989	1,221	1,135	760	1,040	964	1,175	1,106	751	1,007
60-64	1,016	1,177	1,166	756	1,043	1,077	1,308	1,207	777	1,102	1,051	1,248	1,196	773	1,077
65-69	1,059	1,206	1,186	739	1,071	1,117	1,335	1,224	758	1,130	1,087	1,264	1,223	750	1,100
70-79	1,161	1,301	1,271	761	1,153	1,221	1,435	1,306	777	1,206	1,184	1,368	1,301	770	1,174
80+	1,314	1,448	1,404	809	1,298	1,375	1,590	1,437	822	1,371	1,333	1,492	1,404	811	1,320
All	1,007	1,070	1,086	754	1,010	1,019	1,178	1,091	772	1,051	1,013	1,135	1,089	764	1,032
ALL															
0-19	994	1,206	885	849	1,042	1,071	1,404	1,054	1,057	1,166	1,035	1,311	991	889	1,106
20-29	838	933	992	650	864	959	1,091	935	714	992	903	1,021	952	686	935
30-39	972	967	1,081	605	951	1,030	1,081	900	707	1,034	1,002	1,032	968	648	995
40-49	1,014	973	1,108	651	983	1,060	1,101	1,050	656	1,046	1,036	1,041	1,069	655	1,015
50-59	1,125	1,117	1,218	749	1,108	1,188	1,293	1,368	751	1,207	1,154	1,214	1,291	750	1,157
60-64	1,225	1,256	1,192	808	1,215	1,316	1,392	1,441	1,002	1,326	1,268	1,342	1,301	923	1,273
65-69	1,214	1,242	1,255	865	1,210	1,309	1,440	1,433	950	1,318	1,257	1,357	1,351	925	1,263
70-79	1,283	1,321	1,337	821	1,267	1,396	1,512	1,407	828	1,390	1,328	1,427	1,376	824	1,319
80+	1,406	1,399	1,404	850	1,385	1,497	1,616	1,536	888	1,477	1,439	1,552	1,464	869	1,421
All	1,162	1,078	1,177	736	1,124	1,221	1,241	1,174	784	1,202	1,189	1,169	1,175	762	1,162

Includes all patients who have reached day 91 of ESRD by December 31 of each calendar year. Patient age is determined on January 1 of each calendar year.

Table E.5

First Admissions: Transplant Patients

per 1,000 patient years, period prevalent patients, 2000, by primary diagnosis & age

DIABETES	Male					Female					All				
	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All
0-19	947	1,215	1,115	637	978	1,324	1,669	1,575	1,036	1,325	1,324	1,442	1,345	837	1,323
20-29	682	845	781	456	713	909	1,108	1,065	715	968	786	1,000	923	585	840
30-39	609	717	664	394	624	775	908	872	595	796	673	802	764	518	692
40-49	572	684	628	379	584	701	857	791	558	722	618	747	672	440	633
50-59	578	680	628	392	598	703	796	772	550	730	621	731	686	447	647
60-64	668	728	684	435	673	772	830	806	587	786	701	775	716	494	714
65-69	697	763	726	468	699	805	857	818	611	802	737	794	765	522	736
70-79	761	805	762	501	759	827	863	829	630	835	774	833	809	532	780
80+	869	893	845	569	867	904	913	888	689	848	869	903	866	629	866
All	607	710	652	416	623	744	855	795	583	767	656	772	705	482	676
HYPERTENSION															
0-19	495	711	733	352	663	631	896	946	522	708	602	777	945	521	690
20-29	376	526	549	269	459	470	648	684	385	565	407	558	596	287	489
30-39	352	481	498	249	420	417	557	596	342	480	375	502	517	285	439
40-49	368	511	504	258	444	415	545	583	341	477	384	521	527	294	455
50-59	398	509	541	283	454	448	577	603	361	505	415	530	564	325	471
60-64	482	614	634	339	523	517	620	678	416	561	495	617	634	360	538
65-69	554	688	714	387	575	567	678	738	460	603	558	683	726	415	585
70-79	633	763	803	445	644	633	729	799	510	666	633	744	801	446	652
80+	774	903	954	539	809	738	841	915	595	738	756	903	934	567	779
All	435	524	522	292	472	475	588	610	366	522	449	545	547	322	489
GLOMERULONEPHRITIS															
0-19	420	650	472	291	479	558	848	638	452	607	494	723	578	351	542
20-29	316	480	354	224	358	431	609	462	335	481	356	530	407	267	403
30-39	295	428	324	207	325	365	531	406	297	402	321	466	361	251	354
40-49	312	440	328	215	332	372	511	399	298	397	332	470	358	260	355
50-59	349	472	354	235	366	393	538	413	317	413	366	496	378	271	384
60-64	412	554	416	282	426	466	605	467	366	475	428	569	429	321	441
65-69	481	625	469	326	489	512	660	509	407	527	493	640	499	341	504
70-79	552	701	529	375	554	573	710	553	452	575	557	704	529	404	560
80+	672	831	631	456	672	673	813	635	529	672	672	822	633	493	672
All	345	470	351	230	365	412	562	445	315	438	369	505	395	270	392
OTHER															
0-19	460	668	640	362	502	579	842	841	552	625	510	728	753	450	552
20-29	345	502	482	278	367	458	613	612	406	494	395	568	555	345	427
30-39	330	449	437	257	349	410	535	535	362	439	369	501	488	321	395
40-49	339	447	446	266	357	397	528	521	358	422	365	489	488	333	387
50-59	380	485	478	296	398	419	540	540	386	439	400	511	523	348	418
60-64	443	571	559	351	460	481	602	612	443	498	461	586	582	390	478
65-69	522	641	634	405	533	534	660	667	489	546	527	649	634	443	539
70-79	603	718	712	465	611	608	707	723	545	620	605	713	717	544	614
80+	730	853	847	565	734	708	810	829	636	708	724	853	838	601	727
All	389	512	508	295	408	448	578	595	389	471	416	546	557	352	438
ALL															
0-19	453	664	594	332	499	578	846	779	518	625	508	729	704	415	553
20-29	364	519	403	253	400	497	669	515	384	542	418	585	458	308	459
30-39	408	493	448	240	424	500	602	558	356	519	446	538	495	299	463
40-49	409	511	490	258	429	483	576	547	342	495	437	536	511	304	455
50-59	438	542	561	292	463	485	631	656	378	520	457	576	603	333	486
60-64	510	642	650	360	536	550	702	744	463	591	525	669	675	400	557
65-69	563	707	672	418	584	597	729	673	533	621	576	716	673	460	598
70-79	626	760	705	441	635	632	761	829	521	662	628	760	784	463	644
80+	721	898	819	532	739	728	844	817	612	728	723	898	818	572	736
All	441	545	534	289	462	510	637	622	380	536	468	582	571	333	491

Includes all patients who have reached day 91 of ESRD by December 31 of each calendar year.

Patient age is determined on January 1 of each calendar year.

First three years after transplant.

Table E.6
First Admission Standardized Hospitalization Ratios for Selected Years
period prevalent dialysis patients, by state

	1998-2000	1998	1999	2000
Alabama	1.07	1.07	1.08	1.07
Alaska	0.78	0.86	0.81	0.68
Arizona	0.90	0.91	0.93	0.87
Arkansas	1.14	1.13	1.12	1.16
California	0.93	0.94	0.94	0.92
Colorado	0.85	0.86	0.87	0.83
Connecticut	0.93	0.94	0.92	0.94
Delaware	0.91	0.95	0.90	0.88
District of Columbia	1.14	1.15	1.11	1.17
Florida	1.05	1.02	1.05	1.06
Georgia	1.03	1.04	1.03	1.01
Hawaii	1.09	1.15	1.08	1.06
Idaho	0.81	0.84	0.79	0.81
Illinois	1.05	1.05	1.04	1.07
Indiana	0.99	1.01	0.97	0.98
Iowa	0.96	0.94	0.98	0.96
Kansas	1.07	1.05	1.07	1.09
Kentucky	1.05	1.05	1.06	1.05
Louisiana	1.19	1.20	1.17	1.20
Maine	0.95	1.01	0.98	0.88
Maryland	1.06	1.01	1.06	1.11
Massachusetts	1.06	1.03	1.07	1.08
Michigan	0.97	0.96	0.98	0.96
Minnesota	0.93	0.94	0.88	0.97
Mississippi	0.95	0.98	0.94	0.94
Missouri	1.00	0.97	1.00	1.03
Montana	0.80	0.77	0.80	0.82
Nebraska	0.92	0.92	0.89	0.95
Nevada	0.98	1.00	0.96	0.99
New Hampshire	1.02	1.04	1.00	1.00
New Jersey	1.09	1.09	1.07	1.09
New Mexico	0.83	0.91	0.81	0.77
New York	0.93	0.94	0.93	0.93
North Carolina	1.08	1.11	1.11	1.04
North Dakota	0.84	0.82	0.80	0.89
Ohio	1.04	1.02	1.05	1.05
Oklahoma	1.08	1.04	1.07	1.12
Oregon	0.89	0.89	0.89	0.89
Pennsylvania	1.09	1.08	1.10	1.08
Rhode Island	1.05	1.01	1.05	1.07
South Carolina	1.01	0.99	1.01	1.03
South Dakota	0.99	1.05	0.99	0.95
Tennessee	0.98	1.01	0.99	0.95
Texas	0.96	0.96	0.96	0.96
Utah	0.79	0.78	0.79	0.80
Vermont	0.79	0.80	0.82	0.76
Virginia	0.95	0.97	0.96	0.92
Washington	0.86	0.81	0.87	0.89
West Virginia	1.16	1.14	1.17	1.18
Wisconsin	0.92	0.93	0.88	0.96
Wyoming	0.78	0.85	0.73	0.76
American Samoa	1.01	1.41	1.02	0.79
Guam	0.89	0.92	0.92	0.84
Saipan	1.13	1.52	0.94	1.35
Puerto Rico	1.06	1.06	1.04	1.08
Virgin Islands	0.94	0.75	0.92	1.11
All	1.00	1.00	1.00	1.00

Includes all patients who have reached day 91 of ESRD by December 31 of each calendar year.

New to this year's ADR, standard hospitalization ratios are ratios of observed over expected events from the same year(s).

Expected events for the 1998-2000, 1998, 1999, and 2000 standardized hospitalization ratios are calculated based on predicted rates for 1998-2000, 1998, 1999, and 2000, respectively.

Table E.7

Total Admissions: ESRD Patients, 2000

per 1,000 patient years, period prevalent patients, by primary diagnosis & age; grouped by gender & race

DIABETES	Male					Female					All				
	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All
0-19	*	*	.	.	*	*	*	.	.	*	*	*	.	.	*
20-29	2,377	3,254	*	*	2,660	2,879	3,436	2,371	*	3,112	2,626	3,365	2,265	2,358	2,909
30-39	2,369	2,548	2,665	2,115	2,414	2,421	2,801	3,045	1,552	2,542	2,389	2,675	2,844	1,818	2,467
40-49	2,124	2,254	1,796	1,594	2,139	2,507	2,428	2,072	1,693	2,437	2,269	2,338	1,921	1,634	2,264
50-59	2,062	2,081	1,830	1,546	2,041	2,401	2,344	2,203	1,853	2,349	2,208	2,224	2,020	1,679	2,189
60-64	2,147	1,990	1,941	1,709	2,065	2,405	2,183	2,211	1,442	2,264	2,275	2,104	2,083	1,562	2,172
65-69	2,272	2,015	2,171	1,581	2,156	2,395	2,258	2,289	1,677	2,308	2,338	2,171	2,249	1,634	2,244
70-79	2,250	2,107	2,141	1,793	2,193	2,415	2,402	2,203	1,836	2,381	2,339	2,309	2,183	1,819	2,305
80+	2,328	2,389	2,326	1,990	2,324	2,550	2,491	1,963	2,056	2,490	2,445	2,462	2,074	2,029	2,423
All	2,199	2,132	1,972	1,689	2,154	2,430	2,362	2,226	1,769	2,371	2,310	2,270	2,115	1,732	2,269
HYPERTENSION															
0-19	*	1,519	*	*	1,464	421	1,835	*	*	1,763	993	1,702	*	*	1,640
20-29	982	1,126	*	780	1,076	1,492	1,595	2,337	912	1,566	1,180	1,276	1,742	822	1,244
30-39	1,334	1,524	582	1,005	1,462	1,544	1,817	*	1,300	1,739	1,410	1,622	861	1,107	1,556
40-49	1,496	1,503	1,600	728	1,486	1,653	1,834	1,447	1,140	1,769	1,546	1,610	1,546	907	1,578
50-59	1,576	1,520	1,708	1,242	1,530	1,878	1,791	1,391	1,109	1,787	1,685	1,621	1,596	1,182	1,626
60-64	1,923	1,622	1,744	1,543	1,730	2,250	1,774	2,614	1,255	1,926	2,056	1,692	2,170	1,455	1,816
65-69	1,728	1,665	2,030	1,066	1,682	2,127	2,006	2,167	1,267	2,027	1,890	1,844	2,103	1,173	1,844
70-79	1,909	1,930	2,190	1,507	1,902	2,322	2,184	1,831	1,163	2,217	2,079	2,080	1,974	1,335	2,052
80+	2,035	2,273	1,335	1,560	2,061	2,248	2,318	1,619	1,619	2,243	2,129	2,302	1,524	1,591	2,151
All	1,814	1,610	1,628	1,279	1,693	2,165	1,966	1,843	1,270	2,023	1,955	1,766	1,728	1,275	1,833
GLOMERULONEPHRITIS															
0-19	1,499	1,586	*	1,348	1,519	1,390	2,171	*	896	1,629	1,443	1,863	*	1,159	1,573
20-29	1,037	1,196	731	694	1,082	1,562	1,680	1,284	731	1,555	1,255	1,406	1,011	711	1,284
30-39	996	1,289	1,731	944	1,124	1,269	1,562	1,300	878	1,381	1,100	1,407	1,516	919	1,228
40-49	1,243	1,608	1,023	880	1,374	1,403	1,749	1,500	734	1,479	1,301	1,660	1,206	800	1,414
50-59	1,294	1,338	1,621	1,145	1,308	1,526	1,690	2,582	785	1,544	1,386	1,474	2,020	963	1,402
60-64	1,451	1,562	571	1,088	1,452	1,722	1,704	1,878	1,248	1,697	1,553	1,630	1,244	1,153	1,553
65-69	1,499	1,622	1,001	1,156	1,507	1,610	1,871	1,264	1,327	1,657	1,546	1,746	1,132	1,254	1,574
70-79	1,739	1,539	1,547	1,403	1,699	2,076	1,977	2,323	1,310	2,015	1,864	1,773	1,974	1,358	1,827
80+	1,928	2,373	*	1,464	1,955	2,122	2,164	2,511	1,324	2,082	2,005	2,260	2,527	1,385	2,009
All	1,386	1,443	1,272	1,040	1,386	1,636	1,734	1,688	927	1,624	1,483	1,566	1,467	985	1,483
OTHER															
0-19	1,258	1,823	943	1,139	1,416	1,378	2,419	*	1,592	1,658	1,309	2,061	819	1,363	1,517
20-29	1,186	1,634	2,145	941	1,331	1,690	2,137	1,611	1,547	1,850	1,417	1,900	1,837	1,287	1,585
30-39	1,202	1,892	1,988	838	1,474	1,485	2,138	1,991	1,347	1,759	1,336	2,014	1,990	1,106	1,613
40-49	1,312	1,697	1,509	992	1,471	1,568	1,845	1,229	1,099	1,658	1,425	1,763	1,398	1,057	1,555
50-59	1,432	1,486	1,367	858	1,433	1,562	1,809	1,425	1,126	1,624	1,497	1,638	1,395	1,007	1,527
60-64	1,510	1,767	1,772	1,522	1,589	1,742	1,953	720	1,147	1,779	1,625	1,864	1,297	1,311	1,685
65-69	1,685	1,676	2,640	1,446	1,682	1,904	1,915	1,766	1,754	1,901	1,787	1,802	2,204	1,599	1,788
70-79	1,765	1,924	924	1,168	1,772	2,001	2,131	1,706	1,458	2,006	1,870	2,031	1,351	1,327	1,880
80+	1,947	1,958	1,277	1,293	1,930	2,204	2,620	1,703	984	2,242	2,055	2,296	1,490	1,141	2,066
All	1,527	1,722	1,586	1,078	1,574	1,756	2,004	1,509	1,299	1,815	1,632	1,860	1,548	1,200	1,687
ALL															
0-19	1,318	1,773	909	1,228	1,456	1,366	2,319	923	1,581	1,663	1,340	2,011	915	1,398	1,548
20-29	1,227	1,412	1,208	809	1,291	1,775	2,032	1,713	1,213	1,858	1,469	1,690	1,499	1,008	1,546
30-39	1,538	1,676	1,885	1,059	1,589	1,702	2,014	2,041	1,200	1,834	1,605	1,820	1,959	1,121	1,691
40-49	1,615	1,686	1,575	1,039	1,632	1,871	1,969	1,763	1,055	1,878	1,714	1,796	1,653	1,047	1,729
50-59	1,718	1,674	1,760	1,281	1,685	1,971	2,037	2,107	1,296	1,981	1,828	1,839	1,929	1,288	1,817
60-64	1,879	1,797	1,828	1,538	1,833	2,165	2,017	2,138	1,337	2,070	2,013	1,915	1,988	1,442	1,951
65-69	1,930	1,819	2,082	1,400	1,877	2,180	2,134	2,204	1,556	2,138	2,051	2,002	2,159	1,484	2,014
70-79	1,968	1,974	1,961	1,555	1,955	2,278	2,282	2,115	1,545	2,248	2,111	2,166	2,060	1,550	2,106
80+	2,055	2,255	1,888	1,639	2,074	2,302	2,406	1,892	1,670	2,303	2,166	2,352	1,890	1,656	2,188
All	1,807	1,752	1,781	1,324	1,770	2,096	2,114	2,051	1,388	2,074	1,935	1,933	1,924	1,357	1,913

Includes all patients who have reached day 91 of ESRD by December 31 of each calendar year.

Patient age is determined on January 1 of each calendar year.

* Values for cells with fewer than 10 patients are suppressed.

." Zero values in this cell.

Table E.8

Total Admissions: ESRD Patients, 1998-2000 Combined

per 1,000 patient years, period prevalent patients, by primary diagnosis & age; grouped by gender & race

DIABETES	Male					Female					All				
	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All
0-19	*	*	.	.	2,979	*	3,948	.	.	3,588	1,671	4,428	.	.	3,378
20-29	2,354	3,196	2,624	1,770	2,621	2,691	3,415	2,281	2,772	2,979	2,524	3,328	2,342	2,327	2,817
30-39	2,348	2,583	1,981	1,471	2,383	2,399	2,843	2,909	2,100	2,546	2,367	2,712	2,433	1,799	2,451
40-49	2,126	2,256	2,063	1,567	2,151	2,436	2,507	2,155	1,673	2,434	2,245	2,379	2,104	1,614	2,271
50-59	2,105	2,088	1,961	1,594	2,075	2,465	2,347	2,187	1,850	2,379	2,262	2,229	2,076	1,705	2,223
60-64	2,210	2,017	1,978	1,601	2,110	2,474	2,231	2,141	1,587	2,321	2,342	2,146	2,066	1,594	2,225
65-69	2,287	2,028	2,214	1,596	2,172	2,434	2,296	2,131	1,800	2,343	2,367	2,203	2,160	1,706	2,273
70-79	2,326	2,106	2,177	1,728	2,242	2,464	2,415	2,115	1,731	2,406	2,400	2,319	2,135	1,730	2,340
80+	2,403	2,363	2,283	1,743	2,353	2,674	2,561	2,320	1,932	2,586	2,550	2,505	2,310	1,849	2,493
All	2,238	2,143	2,048	1,634	2,182	2,469	2,391	2,179	1,776	2,403	2,350	2,293	2,122	1,709	2,300
HYPERTENSION															
0-19	1,236	902	*	*	1,007	929	2,209	*	*	1,870	1,084	1,458	*	*	1,421
20-29	1,125	1,223	1,559	765	1,188	1,381	1,563	1,943	759	1,496	1,230	1,331	1,800	763	1,295
30-39	1,288	1,577	1,377	1,131	1,501	1,381	1,805	1,406	1,105	1,683	1,321	1,653	1,386	1,122	1,563
40-49	1,406	1,509	1,569	879	1,474	1,546	1,753	1,479	1,263	1,689	1,452	1,588	1,538	1,044	1,544
50-59	1,604	1,491	1,892	1,230	1,520	1,901	1,777	1,484	1,222	1,788	1,711	1,598	1,735	1,226	1,620
60-64	1,891	1,612	1,603	1,313	1,707	2,171	1,728	2,344	1,440	1,868	2,002	1,666	1,999	1,360	1,778
65-69	1,822	1,740	2,262	1,085	1,768	2,190	2,016	2,474	1,327	2,065	1,974	1,884	2,376	1,215	1,908
70-79	1,987	1,890	1,881	1,444	1,942	2,281	2,208	2,117	1,201	2,211	2,107	2,079	2,022	1,326	2,071
80+	2,064	2,257	2,188	1,552	2,084	2,301	2,410	1,982	1,321	2,298	2,168	2,354	2,048	1,430	2,190
All	1,851	1,615	1,760	1,260	1,713	2,150	1,963	1,933	1,259	2,016	1,971	1,768	1,843	1,259	1,842
GLOMERULONEPHRITIS															
0-19	1,456	1,556	910	1,127	1,473	1,415	2,103	1,046	886	1,625	1,436	1,806	1,005	1,018	1,547
20-29	1,089	1,200	1,026	872	1,124	1,519	1,622	1,163	946	1,521	1,268	1,381	1,092	905	1,292
30-39	1,026	1,352	1,274	799	1,147	1,346	1,560	1,237	907	1,411	1,146	1,440	1,255	844	1,253
40-49	1,212	1,585	1,344	879	1,351	1,324	1,654	1,639	786	1,408	1,253	1,610	1,449	830	1,373
50-59	1,302	1,433	1,457	1,058	1,338	1,522	1,627	2,038	941	1,524	1,389	1,509	1,698	999	1,412
60-64	1,568	1,524	832	1,308	1,534	1,638	1,620	2,122	1,553	1,637	1,595	1,569	1,443	1,410	1,577
65-69	1,652	1,712	1,361	1,346	1,650	1,699	1,877	1,020	1,255	1,712	1,671	1,796	1,182	1,297	1,677
70-79	1,720	1,642	2,113	1,258	1,695	2,041	1,951	1,688	1,245	1,975	1,841	1,803	1,910	1,251	1,809
80+	1,929	2,318	1,900	1,458	1,951	2,178	2,133	1,815	1,199	2,114	2,032	2,219	1,846	1,320	2,022
All	1,403	1,474	1,346	1,013	1,406	1,631	1,687	1,512	987	1,606	1,491	1,564	1,422	1,000	1,487
OTHER															
0-19	1,346	1,859	1,133	1,571	1,489	1,445	2,246	2,346	1,353	1,666	1,387	2,017	1,724	1,471	1,562
20-29	1,205	1,605	1,646	991	1,332	1,712	2,201	1,958	1,419	1,881	1,439	1,914	1,812	1,229	1,600
30-39	1,243	1,830	2,196	859	1,472	1,516	2,050	1,779	1,334	1,728	1,372	1,940	1,975	1,131	1,596
40-49	1,280	1,694	1,419	1,040	1,449	1,496	1,912	1,196	1,158	1,647	1,377	1,792	1,326	1,107	1,539
50-59	1,426	1,514	1,339	1,183	1,449	1,611	1,787	1,890	1,169	1,655	1,518	1,645	1,614	1,175	1,551
60-64	1,558	1,772	1,915	1,378	1,623	1,751	1,925	1,313	1,403	1,794	1,655	1,853	1,646	1,391	1,710
65-69	1,714	1,808	2,509	1,404	1,733	1,920	2,033	2,311	1,536	1,942	1,813	1,929	2,406	1,475	1,837
70-79	1,808	1,855	1,995	1,259	1,804	2,023	2,186	1,796	1,572	2,042	1,904	2,029	1,885	1,432	1,915
80+	1,961	2,179	1,439	1,610	1,981	2,189	2,511	2,458	1,461	2,236	2,057	2,357	1,949	1,537	2,094
All	1,540	1,729	1,713	1,189	1,589	1,762	2,015	1,768	1,348	1,828	1,644	1,870	1,740	1,277	1,703
ALL															
0-19	1,370	1,719	1,041	1,394	1,476	1,429	2,213	1,848	1,299	1,669	1,395	1,932	1,505	1,350	1,560
20-29	1,273	1,433	1,357	918	1,329	1,750	2,023	1,703	1,206	1,841	1,486	1,695	1,548	1,056	1,559
30-39	1,547	1,703	1,703	952	1,599	1,720	1,991	1,883	1,251	1,826	1,617	1,825	1,790	1,092	1,693
40-49	1,585	1,683	1,736	1,058	1,620	1,789	1,965	1,829	1,113	1,842	1,666	1,793	1,775	1,085	1,708
50-59	1,732	1,680	1,855	1,335	1,699	2,008	2,026	2,095	1,361	1,996	1,853	1,838	1,972	1,347	1,832
60-64	1,925	1,797	1,857	1,448	1,856	2,178	2,018	2,106	1,526	2,082	2,044	1,917	1,989	1,486	1,969
65-69	1,973	1,870	2,172	1,421	1,923	2,217	2,167	2,107	1,594	2,171	2,092	2,044	2,131	1,514	2,054
70-79	2,020	1,949	2,095	1,501	1,986	2,285	2,297	2,065	1,515	2,256	2,142	2,167	2,076	1,509	2,126
80+	2,081	2,273	2,012	1,609	2,097	2,355	2,464	2,205	1,533	2,353	2,205	2,395	2,142	1,568	2,226
All	1,828	1,758	1,861	1,311	1,785	2,102	2,120	2,031	1,404	2,081	1,950	1,940	1,951	1,358	1,925

Includes all patients who have reached day 91 of ESRD by December 31 of each calendar year.
 Patient age is determined on January 1 of each calendar year.
 * Values for cells with fewer than 10 patients are suppressed.
 "." Zero values in this cell.

Table E.9

Total Admissions: Dialysis Patients, 2000*per 1,000 patient years, period prevalent patients, by primary diagnosis & age; grouped by gender & race*

DIABETES	Male					Female					All				
	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All
0-19	*	*	.	.	*	*	*	.	.	*	*	*	*	*	*
20-29	2,797	3,651	*	*	3,124	3,054	3,828	2,399	*	3,403	2,926	3,758	2,282	2,095	3,280
30-39	2,846	2,734	2,716	2,414	2,803	2,872	2,967	3,094	1,727	2,884	2,856	2,852	2,895	2,069	2,837
40-49	2,415	2,293	1,844	1,638	2,328	2,844	2,452	2,005	1,629	2,599	2,581	2,371	1,918	1,634	2,445
50-59	2,196	2,113	1,879	1,541	2,128	2,495	2,383	2,244	1,873	2,411	2,328	2,261	2,067	1,688	2,267
60-64	2,192	2,002	1,978	1,742	2,095	2,445	2,205	2,199	1,491	2,293	2,322	2,123	2,098	1,601	2,205
65-69	2,305	2,032	2,187	1,614	2,183	2,415	2,261	2,294	1,693	2,319	2,365	2,179	2,258	1,658	2,263
70-79	2,255	2,107	2,151	1,775	2,196	2,413	2,401	2,212	1,838	2,379	2,340	2,308	2,192	1,814	2,305
80+	2,322	2,389	2,326	1,990	2,320	2,550	2,491	1,963	2,056	2,490	2,443	2,462	2,074	2,029	2,421
All	2,305	2,157	2,010	1,713	2,226	2,493	2,379	2,230	1,783	2,410	2,398	2,292	2,136	1,751	2,326
HYPERTENSION															
0-19	*	1,971	*	*	1,750	*	2,097	.	*	2,271	1,296	2,047	*	*	2,043
20-29	1,122	1,096	*	478	1,079	1,306	1,500	2,554	653	1,460	1,193	1,229	1,895	541	1,212
30-39	1,412	1,551	606	1,086	1,510	1,767	1,853	*	1,551	1,831	1,543	1,654	1,013	1,245	1,621
40-49	1,576	1,504	1,700	776	1,507	1,854	1,875	1,461	1,432	1,854	1,665	1,625	1,616	1,071	1,620
50-59	1,701	1,557	1,563	1,309	1,588	2,022	1,812	1,422	1,236	1,843	1,817	1,653	1,514	1,278	1,683
60-64	1,988	1,631	1,792	1,465	1,751	2,352	1,798	2,608	1,354	1,969	2,138	1,708	2,199	1,429	1,848
65-69	1,773	1,663	2,030	1,132	1,706	2,162	2,027	2,167	1,275	2,054	1,934	1,855	2,103	1,210	1,872
70-79	1,921	1,935	2,190	1,528	1,913	2,330	2,194	1,831	1,157	2,224	2,090	2,087	1,974	1,341	2,062
80+	2,037	2,275	1,335	1,560	2,062	2,249	2,318	1,619	1,619	2,244	2,130	2,303	1,524	1,591	2,152
All	1,868	1,632	1,664	1,331	1,731	2,222	1,992	1,883	1,329	2,064	2,012	1,793	1,769	1,330	1,875
GLOMERULONEPHRITIS															
0-19	1,788	1,293	*	*	1,567	1,644	2,045	*	*	1,791	1,714	1,690	*	1,437	1,683
20-29	1,178	1,156	824	633	1,131	1,562	1,701	1,163	611	1,566	1,344	1,396	997	623	1,322
30-39	1,073	1,332	1,863	864	1,193	1,445	1,599	1,415	942	1,502	1,216	1,449	1,628	891	1,320
40-49	1,420	1,660	1,116	893	1,507	1,561	1,860	1,410	704	1,618	1,473	1,731	1,223	790	1,549
50-59	1,364	1,374	1,663	1,220	1,367	1,741	1,753	2,876	829	1,701	1,518	1,521	2,179	1,016	1,503
60-64	1,640	1,548	421	1,296	1,577	1,809	1,717	1,939	1,591	1,767	1,706	1,632	1,240	1,408	1,659
65-69	1,576	1,583	1,039	1,269	1,559	1,717	1,892	1,249	1,276	1,734	1,637	1,738	1,134	1,273	1,639
70-79	1,757	1,535	1,561	1,406	1,712	2,090	1,966	2,323	1,310	2,024	1,882	1,767	1,982	1,360	1,840
80+	1,932	2,373	*	1,464	1,959	2,122	2,164	2,511	1,324	2,082	2,008	2,260	2,527	1,385	2,012
All	1,519	1,471	1,338	1,087	1,480	1,784	1,783	1,786	972	1,735	1,624	1,605	1,548	1,032	1,585
OTHER															
0-19	1,669	2,121	*	975	1,802	1,829	2,624	*	*	2,139	1,737	2,347	*	1,493	1,948
20-29	1,367	1,611	2,368	1,028	1,460	1,925	2,298	1,553	1,749	2,071	1,620	1,970	1,896	1,449	1,759
30-39	1,316	1,979	2,236	783	1,615	1,654	2,296	2,027	1,676	1,966	1,473	2,133	2,120	1,229	1,782
40-49	1,498	1,767	1,567	1,090	1,620	1,818	1,890	1,328	1,432	1,829	1,639	1,821	1,475	1,281	1,712
50-59	1,570	1,480	1,362	736	1,506	1,782	1,860	1,541	1,128	1,783	1,677	1,658	1,447	952	1,642
60-64	1,620	1,796	1,885	1,607	1,680	1,925	1,999	737	1,179	1,913	1,773	1,904	1,356	1,355	1,800
65-69	1,731	1,666	2,627	1,482	1,712	2,019	1,943	1,766	1,802	1,987	1,867	1,813	2,163	1,643	1,847
70-79	1,778	1,937	924	1,136	1,784	2,012	2,148	1,706	1,468	2,019	1,883	2,046	1,351	1,317	1,893
80+	1,946	1,956	1,277	1,293	1,928	2,206	2,620	1,703	984	2,243	2,055	2,296	1,490	1,141	2,065
All	1,655	1,762	1,648	1,088	1,673	1,927	2,072	1,576	1,435	1,954	1,780	1,912	1,613	1,276	1,806
ALL															
0-19	1,700	1,910	*	1,372	1,758	1,755	2,394	*	2,088	2,041	1,725	2,147	1,005	1,724	1,890
20-29	1,408	1,411	1,352	777	1,383	1,886	2,120	1,740	1,230	1,967	1,620	1,731	1,580	1,006	1,648
30-39	1,750	1,740	2,056	1,078	1,727	1,941	2,105	2,134	1,428	2,015	1,827	1,895	2,094	1,223	1,847
40-49	1,833	1,715	1,650	1,110	1,745	2,141	2,023	1,754	1,200	2,030	1,953	1,835	1,694	1,155	1,857
50-59	1,866	1,707	1,786	1,302	1,770	2,154	2,081	2,180	1,375	2,092	1,993	1,878	1,979	1,337	1,915
60-64	1,977	1,810	1,865	1,581	1,890	2,269	2,044	2,140	1,422	2,131	2,118	1,936	2,012	1,502	2,013
65-69	1,986	1,823	2,097	1,452	1,913	2,240	2,146	2,219	1,570	2,175	2,111	2,013	2,174	1,516	2,053
70-79	1,980	1,978	1,968	1,551	1,965	2,284	2,286	2,121	1,548	2,253	2,122	2,170	2,066	1,549	2,114
80+	2,055	2,256	1,888	1,639	2,074	2,303	2,406	1,892	1,670	2,303	2,166	2,352	1,890	1,656	2,189
All	1,924	1,783	1,836	1,376	1,850	2,216	2,151	2,087	1,469	2,156	2,056	1,970	1,971	1,424	1,997

Includes all patients who have reached day 91 of ESRD by December 31 of each calendar year.

Patient age is determined on January 1 of each calendar year.

* Values for cells with fewer than 10 patients are suppressed.

." Zero values in this cell.

Table E.10

Total Admissions: Dialysis Patients, 1998-2000 Combined

per 1,000 patient years, period prevalent patients, by primary diagnosis & age; grouped by gender & race

DIABETES	Male					Female					All				
	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All
0-19	*	*	.	.	.	*	4,143	.	.	.	4,657	*	4,772	.	4,601
20-29	2,740	3,518	3,103	1,911	3,024	3,068	3,744	2,122	2,581	3,348	2,906	3,656	2,288	2,254	3,205
30-39	2,812	2,754	2,050	1,678	2,759	2,906	3,029	2,809	2,186	2,932	2,846	2,891	2,422	1,938	2,829
40-49	2,419	2,278	2,084	1,674	2,337	2,741	2,534	2,203	1,706	2,598	2,545	2,406	2,138	1,688	2,451
50-59	2,225	2,116	2,002	1,633	2,153	2,557	2,373	2,229	1,872	2,434	2,374	2,258	2,119	1,739	2,293
60-64	2,278	2,028	2,038	1,667	2,154	2,515	2,246	2,168	1,634	2,348	2,400	2,161	2,109	1,649	2,262
65-69	2,332	2,036	2,217	1,615	2,202	2,449	2,298	2,137	1,807	2,352	2,397	2,208	2,164	1,719	2,291
70-79	2,333	2,109	2,179	1,727	2,248	2,465	2,415	2,118	1,734	2,407	2,404	2,320	2,138	1,732	2,343
80+	2,400	2,363	2,283	1,743	2,351	2,674	2,561	2,320	1,932	2,586	2,549	2,505	2,310	1,849	2,493
All	2,352	2,161	2,083	1,674	2,257	2,539	2,406	2,193	1,789	2,444	2,445	2,311	2,146	1,736	2,359
HYPERTENSION															
0-19	1,582	995	*	*	1,140	696	2,305	.	*	2,091	1,190	1,607	*	*	1,590
20-29	1,206	1,196	1,665	667	1,189	1,354	1,536	2,266	693	1,483	1,270	1,304	2,027	676	1,292
30-39	1,419	1,615	1,357	1,239	1,570	1,525	1,846	1,514	1,161	1,766	1,458	1,693	1,407	1,211	1,637
40-49	1,490	1,520	1,663	890	1,505	1,719	1,789	1,406	1,480	1,762	1,564	1,608	1,570	1,142	1,589
50-59	1,738	1,519	1,894	1,283	1,574	2,043	1,800	1,507	1,325	1,843	1,850	1,626	1,744	1,302	1,676
60-64	1,995	1,612	1,611	1,331	1,741	2,277	1,743	2,388	1,484	1,906	2,109	1,674	2,028	1,392	1,815
65-69	1,858	1,733	2,319	1,070	1,783	2,232	2,024	2,474	1,333	2,086	2,015	1,886	2,404	1,215	1,928
70-79	1,997	1,893	1,881	1,448	1,950	2,288	2,214	2,117	1,196	2,217	2,116	2,084	2,022	1,325	2,078
80+	2,065	2,260	2,188	1,552	2,085	2,302	2,410	1,982	1,321	2,298	2,169	2,355	2,048	1,430	2,191
All	1,914	1,637	1,804	1,301	1,755	2,210	1,989	1,970	1,296	2,057	2,034	1,795	1,885	1,299	1,886
GLOMERULONEPHRITIS															
0-19	1,732	1,524	*	1,175	1,600	1,692	1,988	1,362	617	1,766	1,713	1,757	1,242	914	1,682
20-29	1,284	1,173	1,023	851	1,201	1,589	1,640	940	995	1,564	1,416	1,378	983	917	1,361
30-39	1,150	1,405	1,369	805	1,251	1,541	1,612	1,303	977	1,542	1,300	1,494	1,334	871	1,370
40-49	1,366	1,636	1,442	885	1,473	1,458	1,735	1,688	795	1,527	1,401	1,671	1,523	839	1,493
50-59	1,416	1,449	1,526	1,133	1,418	1,718	1,659	2,277	1,034	1,660	1,539	1,532	1,838	1,084	1,516
60-64	1,746	1,551	772	1,504	1,662	1,772	1,658	2,174	1,756	1,737	1,756	1,602	1,503	1,603	1,694
65-69	1,735	1,734	1,463	1,470	1,722	1,793	1,886	939	1,214	1,772	1,759	1,813	1,189	1,326	1,744
70-79	1,732	1,630	2,160	1,258	1,703	2,057	1,954	1,688	1,240	1,986	1,856	1,800	1,931	1,249	1,820
80+	1,930	2,318	1,900	1,458	1,952	2,181	2,133	1,815	1,199	2,116	2,034	2,219	1,846	1,320	2,023
All	1,547	1,511	1,430	1,070	1,511	1,782	1,729	1,560	1,047	1,715	1,640	1,604	1,490	1,059	1,595
OTHER															
0-19	1,799	2,091	1,035	1,884	1,892	1,884	2,372	2,277	1,394	2,052	1,835	2,220	1,626	1,623	1,963
20-29	1,354	1,656	2,047	1,094	1,470	1,967	2,316	2,194	1,627	2,106	1,634	1,999	2,127	1,406	1,781
30-39	1,368	1,908	2,415	942	1,614	1,708	2,190	1,792	1,532	1,926	1,526	2,045	2,091	1,265	1,763
40-49	1,451	1,738	1,468	1,154	1,582	1,730	1,977	1,348	1,298	1,821	1,578	1,843	1,421	1,234	1,690
50-59	1,598	1,516	1,343	1,079	1,547	1,831	1,844	2,153	1,160	1,814	1,715	1,673	1,723	1,124	1,679
60-64	1,694	1,815	2,117	1,444	1,733	1,918	1,956	1,340	1,442	1,912	1,808	1,891	1,778	1,443	1,826
65-69	1,759	1,821	2,337	1,407	1,768	2,004	2,052	2,134	1,651	2,007	1,878	1,946	2,226	1,538	1,889
70-79	1,821	1,855	1,995	1,243	1,813	2,034	2,195	1,796	1,561	2,052	1,917	2,034	1,885	1,418	1,926
80+	1,964	2,184	1,439	1,610	1,983	2,189	2,511	2,458	1,461	2,237	2,059	2,360	1,949	1,537	2,096
All	1,677	1,767	1,795	1,227	1,695	1,931	2,079	1,856	1,441	1,963	1,795	1,921	1,825	1,344	1,824
ALL															
0-19	1,774	1,841	949	1,529	1,781	1,813	2,255	1,813	1,333	1,978	1,792	2,039	1,436	1,427	1,871
20-29	1,453	1,446	1,516	942	1,431	1,928	2,100	1,731	1,315	1,980	1,668	1,739	1,637	1,129	1,680
30-39	1,777	1,769	1,818	1,025	1,750	1,969	2,084	1,892	1,404	2,006	1,854	1,902	1,854	1,195	1,857
40-49	1,794	1,711	1,799	1,130	1,730	2,032	2,019	1,900	1,223	1,989	1,889	1,831	1,841	1,176	1,833
50-59	1,891	1,707	1,893	1,375	1,786	2,193	2,063	2,171	1,438	2,102	2,025	1,871	2,030	1,405	1,930
60-64	2,046	1,811	1,923	1,528	1,927	2,289	2,040	2,146	1,587	2,143	2,163	1,936	2,043	1,557	2,038
65-69	2,031	1,875	2,176	1,445	1,959	2,269	2,174	2,103	1,614	2,201	2,149	2,052	2,129	1,537	2,090
70-79	2,032	1,951	2,100	1,500	1,995	2,292	2,301	2,067	1,514	2,261	2,153	2,170	2,079	1,508	2,134
80+	2,081	2,276	2,012	1,609	2,098	2,356	2,464	2,205	1,533	2,354	2,206	2,397	2,142	1,568	2,227
All	1,955	1,789	1,920	1,371	1,871	2,227	2,155	2,071	1,473	2,165	2,079	1,977	2,001	1,424	2,013

Includes all patients who have reached day 91 of ESRD by December 31 of each calendar year.

Patient age is determined on January 1 of each calendar year.

* Values for cells with fewer than 10 patients are suppressed.

." Zero values in this cell.

Table E.11

Total Admissions: Hemodialysis Patients, 2000

per 1,000 patient years, period prevalent patients, by primary diagnosis & age; grouped by gender & race

DIABETES	Male					Female					All				
	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All
0-19	*	*	.	.	*	*	*	*	.	.	*
20-29	2,844	3,637	*	*	3,168	3,407	3,719	2,316	*	3,478	3,098	3,686	2,356	1,184	3,335
30-39	2,816	2,754	3,056	2,420	2,794	2,980	2,920	2,802	1,809	2,909	2,872	2,836	2,934	2,116	2,840
40-49	2,426	2,302	1,876	1,548	2,331	2,831	2,401	1,896	1,778	2,558	2,579	2,350	1,885	1,636	2,428
50-59	2,191	2,107	1,843	1,506	2,118	2,465	2,359	2,257	1,830	2,385	2,313	2,244	2,055	1,651	2,250
60-64	2,152	1,980	1,957	1,708	2,060	2,422	2,191	2,134	1,592	2,274	2,291	2,106	2,053	1,643	2,179
65-69	2,296	2,014	2,256	1,658	2,171	2,416	2,261	2,306	1,685	2,320	2,362	2,174	2,289	1,673	2,259
70-79	2,255	2,107	2,106	1,805	2,195	2,402	2,384	2,171	1,818	2,365	2,336	2,297	2,150	1,813	2,297
80+	2,325	2,376	2,326	2,011	2,320	2,555	2,489	2,002	1,945	2,488	2,448	2,456	2,103	1,973	2,420
All	2,294	2,147	2,013	1,715	2,214	2,479	2,358	2,198	1,776	2,392	2,387	2,276	2,119	1,748	2,311
HYPERTENSION															
0-19	*	2,068	*	.	1,819	*	2,282	.	*	2,161	*	2,196	*	*	2,029
20-29	977	1,099	*	557	1,060	1,523	1,414	3,011	*	1,480	1,175	1,195	2,107	579	1,194
30-39	1,398	1,523	540	1,147	1,488	1,766	1,845	*	1,449	1,826	1,527	1,630	888	1,236	1,601
40-49	1,585	1,516	1,733	811	1,519	1,995	1,919	1,144	1,690	1,918	1,712	1,643	1,558	1,185	1,646
50-59	1,725	1,534	1,600	1,306	1,575	2,075	1,794	1,445	1,198	1,842	1,852	1,629	1,545	1,263	1,672
60-64	2,035	1,615	1,477	1,416	1,744	2,437	1,802	2,572	1,549	1,992	2,198	1,700	2,044	1,457	1,852
65-69	1,760	1,656	1,972	1,105	1,692	2,223	2,013	2,244	1,372	2,072	1,951	1,843	2,127	1,244	1,873
70-79	1,932	1,937	2,266	1,542	1,922	2,346	2,195	1,814	1,078	2,228	2,103	2,090	1,993	1,304	2,070
80+	2,044	2,249	1,335	1,551	2,064	2,254	2,325	1,619	1,555	2,248	2,137	2,297	1,524	1,553	2,155
All	1,883	1,627	1,649	1,345	1,733	2,259	2,001	1,892	1,318	2,084	2,036	1,792	1,764	1,332	1,883
GLOMERULONEPHRITIS															
0-19	2,082	1,274	*	*	1,715	2,012	2,012	.	*	1,923	2,052	1,657	*	1,509	1,816
20-29	1,114	1,127	755	670	1,091	1,496	1,626	1,317	677	1,512	1,268	1,338	1,008	674	1,266
30-39	1,100	1,337	1,741	938	1,216	1,488	1,610	1,560	1,030	1,534	1,236	1,448	1,664	970	1,337
40-49	1,418	1,674	1,126	922	1,519	1,639	1,899	1,550	788	1,692	1,496	1,748	1,252	856	1,580
50-59	1,379	1,355	1,730	1,346	1,373	1,773	1,724	2,978	859	1,717	1,535	1,494	2,260	1,103	1,508
60-64	1,650	1,525	337	1,316	1,578	1,895	1,748	1,942	1,506	1,821	1,744	1,631	1,315	1,392	1,680
65-69	1,623	1,557	1,042	1,140	1,581	1,759	1,875	1,249	1,132	1,745	1,682	1,712	1,140	1,135	1,655
70-79	1,768	1,551	1,561	1,361	1,719	2,108	1,982	2,298	1,352	2,039	1,897	1,782	1,965	1,356	1,851
80+	1,931	2,414	*	1,476	1,964	2,106	2,176	2,329	1,280	2,068	2,002	2,285	2,421	1,368	2,008
All	1,535	1,471	1,334	1,130	1,491	1,835	1,787	1,929	1,025	1,770	1,651	1,600	1,594	1,080	1,602
OTHER															
0-19	1,946	2,156	*	*	1,994	1,953	2,891	.	*	2,364	1,948	2,485	*	*	2,145
20-29	1,323	1,645	2,558	943	1,450	2,013	2,401	1,796	1,792	2,173	1,621	2,027	2,117	1,400	1,789
30-39	1,299	1,960	2,357	665	1,603	1,708	2,255	1,938	1,773	1,985	1,477	2,098	2,134	1,188	1,776
40-49	1,491	1,780	1,562	1,075	1,627	1,846	1,898	1,432	1,604	1,857	1,640	1,829	1,519	1,357	1,723
50-59	1,583	1,453	1,381	747	1,501	1,796	1,900	1,614	1,124	1,808	1,687	1,656	1,495	954	1,648
60-64	1,622	1,819	1,877	1,657	1,692	1,929	1,974	795	1,214	1,908	1,773	1,900	1,382	1,403	1,801
65-69	1,754	1,661	2,627	1,428	1,725	2,083	1,930	1,408	1,917	2,024	1,908	1,804	2,018	1,674	1,871
70-79	1,763	1,918	929	1,135	1,769	2,041	2,102	1,482	1,510	2,032	1,889	2,013	1,216	1,340	1,893
80+	1,934	1,960	1,429	1,361	1,922	2,173	2,605	1,703	992	2,217	2,035	2,290	1,574	1,176	2,051
All	1,655	1,758	1,673	1,082	1,674	1,963	2,074	1,551	1,477	1,980	1,794	1,907	1,616	1,292	1,815
ALL															
0-19	1,980	1,943	*	*	1,941	1,939	2,512	.	1,249	2,205	1,963	2,219	*	1,514	2,058
20-29	1,358	1,409	1,360	793	1,364	1,955	2,114	1,969	1,192	2,004	1,607	1,713	1,705	983	1,639
30-39	1,725	1,723	2,124	1,124	1,711	1,994	2,090	2,141	1,493	2,034	1,826	1,872	2,132	1,272	1,838
40-49	1,831	1,727	1,673	1,109	1,750	2,187	2,041	1,708	1,375	2,064	1,965	1,845	1,687	1,233	1,869
50-59	1,877	1,692	1,773	1,313	1,764	2,167	2,075	2,201	1,386	2,096	2,004	1,864	1,983	1,347	1,912
60-64	1,966	1,795	1,829	1,567	1,874	2,280	2,040	2,091	1,504	2,132	2,118	1,926	1,970	1,536	2,005
65-69	1,993	1,811	2,146	1,452	1,911	2,273	2,142	2,221	1,587	2,190	2,132	2,005	2,194	1,524	2,061
70-79	1,984	1,978	1,944	1,564	1,968	2,293	2,275	2,074	1,528	2,251	2,129	2,163	2,028	1,543	2,116
80+	2,056	2,242	1,935	1,655	2,074	2,299	2,408	1,896	1,597	2,299	2,166	2,348	1,910	1,624	2,188
All	1,929	1,780	1,841	1,396	1,850	2,241	2,151	2,085	1,493	2,170	2,070	1,967	1,972	1,445	2,003

Includes all patients who have reached day 91 of ESRD by December 31 of each calendar year.

Patient age is determined on January 1 of each calendar year.

* Values for cells with fewer than 10 patients are suppressed.

." Zero values in this cell.

Table E.12
Total Admissions: Hemodialysis Patients, 1998-2000 Combined
per 1,000 patient years, period prevalent patients, by primary diagnosis & age; grouped by gender & race

DIABETES	Male					Female					All				
	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All
0-19	*	*	.	.	*	*	4,719	.	.	.	4,507
20-29	2,756	3,525	*	1,123	3,024	3,340	3,714	1,972	1,836	3,465	3,030	3,641	2,056	1,468	3,265
30-39	2,793	2,790	2,263	1,680	2,757	2,974	3,038	2,762	2,008	2,964	2,854	2,911	2,507	1,843	2,839
40-49	2,441	2,275	2,043	1,677	2,340	2,754	2,479	2,108	1,807	2,569	2,561	2,376	2,072	1,732	2,440
50-59	2,203	2,091	1,962	1,601	2,127	2,509	2,346	2,212	1,817	2,395	2,342	2,231	2,090	1,698	2,261
60-64	2,240	2,006	2,017	1,619	2,118	2,483	2,221	2,108	1,644	2,317	2,366	2,137	2,067	1,633	2,230
65-69	2,314	2,009	2,270	1,674	2,181	2,435	2,288	2,139	1,761	2,338	2,382	2,193	2,182	1,721	2,276
70-79	2,314	2,104	2,170	1,712	2,230	2,450	2,392	2,087	1,710	2,387	2,389	2,303	2,114	1,711	2,325
80+	2,385	2,333	2,283	1,755	2,332	2,676	2,557	2,305	1,902	2,584	2,543	2,493	2,299	1,836	2,485
All	2,332	2,143	2,072	1,668	2,235	2,518	2,380	2,159	1,760	2,419	2,426	2,289	2,122	1,717	2,336
HYPERTENSION															
0-19	1,309	992	*	.	1,022	1,061	2,517	.	*	2,404	1,197	1,627	*	*	1,617
20-29	1,149	1,170	1,655	684	1,161	1,515	1,497	2,523	718	1,517	1,297	1,267	2,126	694	1,276
30-39	1,403	1,606	1,417	1,209	1,563	1,517	1,858	2,278	1,045	1,785	1,443	1,688	1,599	1,158	1,636
40-49	1,496	1,521	1,661	763	1,505	1,790	1,824	1,388	1,555	1,806	1,589	1,616	1,571	1,094	1,601
50-59	1,744	1,497	1,875	1,332	1,556	2,101	1,775	1,566	1,354	1,838	1,874	1,600	1,750	1,341	1,660
60-64	1,992	1,598	1,343	1,356	1,721	2,311	1,734	2,361	1,733	1,906	2,119	1,661	1,898	1,498	1,803
65-69	1,858	1,714	2,125	1,013	1,767	2,282	2,017	2,386	1,398	2,098	2,036	1,873	2,275	1,222	1,926
70-79	2,000	1,888	1,915	1,458	1,950	2,293	2,210	2,111	1,155	2,215	2,120	2,081	2,033	1,307	2,078
80+	2,075	2,241	2,207	1,532	2,090	2,307	2,409	2,007	1,288	2,302	2,177	2,348	2,072	1,402	2,195
All	1,923	1,628	1,764	1,297	1,751	2,239	1,997	2,018	1,301	2,073	2,051	1,793	1,888	1,299	1,890
GLOMERULONEPHRITIS															
0-19	1,775	1,532	*	1,676	1,640	1,966	1,860	*	584	1,792	1,848	1,689	868	1,092	1,708
20-29	1,241	1,124	894	902	1,157	1,586	1,553	1,093	1,136	1,531	1,377	1,302	981	1,007	1,310
30-39	1,133	1,366	1,283	836	1,231	1,575	1,643	1,544	1,053	1,584	1,289	1,477	1,390	915	1,364
40-49	1,364	1,654	1,489	913	1,489	1,513	1,781	1,601	888	1,591	1,416	1,696	1,522	901	1,525
50-59	1,413	1,430	1,609	1,170	1,412	1,745	1,652	2,352	1,139	1,682	1,543	1,514	1,921	1,155	1,518
60-64	1,750	1,528	862	1,527	1,654	1,813	1,659	2,067	1,714	1,755	1,774	1,588	1,536	1,602	1,696
65-69	1,743	1,709	1,459	1,404	1,720	1,809	1,895	936	1,049	1,774	1,770	1,803	1,188	1,199	1,744
70-79	1,726	1,632	2,053	1,284	1,697	2,068	1,966	1,732	1,275	1,997	1,858	1,807	1,899	1,280	1,822
80+	1,928	2,326	1,764	1,418	1,949	2,192	2,147	1,736	1,205	2,125	2,038	2,229	1,747	1,305	2,027
All	1,546	1,499	1,427	1,103	1,507	1,828	1,740	1,648	1,117	1,751	1,654	1,597	1,522	1,110	1,604
OTHER															
0-19	1,716	1,987	1,035	2,226	1,811	1,971	2,235	1,445	868	2,033	1,818	2,101	1,190	1,377	1,907
20-29	1,342	1,640	2,124	1,054	1,460	1,956	2,327	2,618	1,715	2,125	1,604	1,987	2,377	1,420	1,770
30-39	1,343	1,901	2,675	797	1,605	1,759	2,157	1,871	1,557	1,947	1,524	2,019	2,276	1,189	1,759
40-49	1,460	1,743	1,421	1,150	1,592	1,738	1,964	1,338	1,409	1,830	1,580	1,836	1,392	1,287	1,694
50-59	1,603	1,488	1,317	1,068	1,535	1,869	1,860	2,079	1,172	1,842	1,733	1,661	1,683	1,124	1,683
60-64	1,711	1,802	2,220	1,483	1,742	1,939	1,940	1,288	1,497	1,920	1,824	1,875	1,819	1,490	1,833
65-69	1,783	1,809	2,337	1,383	1,782	2,031	2,042	1,809	1,721	2,022	1,903	1,936	2,074	1,560	1,903
70-79	1,812	1,850	1,923	1,256	1,807	2,050	2,174	1,782	1,636	2,063	1,921	2,021	1,847	1,467	1,928
80+	1,961	2,175	1,492	1,706	1,984	2,176	2,510	2,458	1,476	2,229	2,052	2,355	2,004	1,592	2,093
All	1,680	1,757	1,824	1,222	1,695	1,960	2,068	1,856	1,495	1,981	1,808	1,907	1,839	1,368	1,829
ALL															
0-19	1,722	1,761	919	1,912	1,729	1,972	2,138	1,209	989	1,993	1,822	1,937	1,053	1,366	1,844
20-29	1,427	1,411	1,460	933	1,401	1,967	2,080	1,962	1,405	2,002	1,653	1,698	1,723	1,159	1,658
30-39	1,734	1,756	1,895	1,015	1,727	2,002	2,092	2,103	1,413	2,033	1,835	1,891	1,985	1,183	1,847
40-49	1,798	1,714	1,786	1,129	1,732	2,070	2,029	1,856	1,348	2,016	1,902	1,833	1,814	1,230	1,840
50-59	1,886	1,684	1,869	1,377	1,769	2,204	2,052	2,160	1,465	2,101	2,026	1,851	2,012	1,418	1,918
60-64	2,031	1,793	1,902	1,522	1,906	2,292	2,026	2,089	1,638	2,134	2,157	1,920	2,003	1,579	2,023
65-69	2,033	1,852	2,190	1,453	1,950	2,284	2,167	2,082	1,600	2,203	2,159	2,039	2,121	1,532	2,088
70-79	2,027	1,947	2,082	1,507	1,990	2,294	2,286	2,048	1,506	2,257	2,152	2,160	2,060	1,507	2,130
80+	2,083	2,257	2,030	1,615	2,098	2,359	2,462	2,198	1,510	2,355	2,208	2,389	2,144	1,559	2,229
All	1,953	1,779	1,914	1,381	1,864	2,247	2,153	2,070	1,498	2,174	2,087	1,969	1,998	1,440	2,013

Includes all patients who have reached day 91 of ESRD by December 31 of each calendar year.

Patient age is determined on January 1 of each calendar year.

* Values for cells with fewer than 10 patients are suppressed.

." Zero patients in this cell.

Table E.13

Total Admissions: CAPD/CCPD Patients, 2000

per 1,000 patient years, period prevalent patients, by primary diagnosis & age; grouped by gender & race

DIABETES	Male					Female					All				
	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All
0-19
20-29	2,569	4,404	*	*	2,974	2,256	4,844	*	*	3,171	2,355	4,716	*	*	3,110
30-39	2,979	2,508	*	*	2,836	2,565	3,361	*	*	2,762	2,790	2,998	1,816	*	2,800
40-49	2,354	2,144	1,578	2,786	2,301	2,938	3,153	2,797	870	2,917	2,603	2,656	2,325	1,655	2,581
50-59	2,196	2,149	2,320	1,761	2,176	2,746	2,811	2,115	2,446	2,726	2,428	2,559	2,208	2,038	2,440
60-64	2,519	2,502	2,652	2,122	2,506	2,669	2,574	3,522	693	2,573	2,588	2,546	3,117	1,257	2,540
65-69	2,314	2,211	1,089	898	2,226	2,344	2,316	1,961	1,633	2,273	2,328	2,279	1,616	1,422	2,250
70-79	2,242	1,895	2,814	1,313	2,176	2,555	3,027	3,602	2,360	2,680	2,380	2,640	3,191	1,782	2,417
80+	2,216	*	.	*	2,277	2,476	3,082	*	*	2,731	2,323	3,258	*	3,514	2,496
All	2,367	2,261	2,034	1,648	2,319	2,624	2,882	2,556	1,842	2,664	2,481	2,641	2,320	1,757	2,488
HYPERTENSION															
0-19	*	*	.	*	*	*	*	.	*	*	*	*	.	*	2,214
20-29	601	1,055	*	*	821	770	1,941	*	*	1,399	683	1,525	*	354	1,116
30-39	1,491	1,940	*	*	1,750	1,779	1,936	*	*	1,873	1,625	1,938	*	1,355	1,808
40-49	1,493	1,264	*	561	1,318	1,144	1,534	*	554	1,418	1,366	1,389	2,252	557	1,362
50-59	1,558	1,877	*	1,338	1,707	1,656	1,935	*	1,193	1,806	1,593	1,907	*	1,257	1,753
60-64	1,665	2,110	*	*	1,862	1,925	1,769	*	*	1,799	1,780	1,890	*	1,198	1,829
65-69	1,864	1,836	*	*	1,858	1,738	2,308	*	727	1,844	1,810	2,107	*	936	1,851
70-79	1,774	1,876	*	1,382	1,767	2,121	2,174	*	2,524	2,147	1,912	2,024	*	1,829	1,924
80+	1,834	4,453	.	1,735	1,957	2,156	2,071	.	*	2,191	1,961	2,972	.	2,307	2,055
All	1,696	1,697	1,928	1,216	1,680	1,854	1,875	1,803	1,383	1,839	1,760	1,788	1,864	1,303	1,752
GLOMERULONEPHRITIS															
0-19	1,294	1,458	*	*	1,301	1,426	1,796	*	*	1,551	1,375	1,650	*	*	1,445
20-29	1,510	1,437	*	446	1,404	1,674	2,085	*	335	1,733	1,600	1,809	950	391	1,589
30-39	886	1,266	*	559	958	1,278	1,616	1,194	560	1,394	1,096	1,502	1,066	559	1,213
40-49	1,411	1,559	*	191	1,392	1,331	1,634	*	521	1,342	1,371	1,601	1,006	429	1,365
50-59	1,268	1,616	*	624	1,311	1,562	1,958	*	769	1,602	1,407	1,794	1,615	710	1,456
60-64	1,603	1,868	*	*	1,571	1,367	1,565	*	*	1,463	1,498	1,643	*	*	1,517
65-69	1,330	2,007	*	*	1,426	1,420	2,017	.	*	1,618	1,369	2,014	*	*	1,515
70-79	1,620	1,145	.	*	1,586	1,952	1,679	*	*	1,887	1,738	1,467	*	1,033	1,700
80+	1,843	*	.	*	1,802	2,398	*	*	*	2,294	2,038	*	*	*	1,986
All	1,398	1,501	920	669	1,374	1,530	1,755	1,229	759	1,546	1,459	1,653	1,123	718	1,462
OTHER															
0-19	1,218	1,898	.	*	1,418	1,691	2,138	*	*	1,866	1,457	2,018	*	1,974	1,643
20-29	1,553	1,434	*	*	1,492	1,620	1,821	*	1,489	1,669	1,591	1,675	*	1,390	1,598
30-39	1,400	2,136	*	1,262	1,676	1,450	2,520	*	1,431	1,897	1,431	2,377	2,278	1,361	1,813
40-49	1,500	1,532	*	1,242	1,501	1,704	1,906	1,036	903	1,724	1,620	1,771	1,194	1,016	1,637
50-59	1,434	1,854	*	795	1,503	1,708	1,535	*	1,168	1,637	1,596	1,651	*	1,022	1,583
60-64	1,591	1,394	*	*	1,539	1,922	2,762	*	*	2,025	1,789	2,190	*	*	1,831
65-69	1,479	1,727	.	*	1,523	1,644	2,247	*	*	1,706	1,560	1,982	*	1,303	1,614
70-79	1,906	2,603	*	1,145	1,922	1,608	3,526	*	1,089	1,798	1,792	3,089	*	1,115	1,872
80+	2,153	*	*	*	2,056	2,957	*	.	*	3,009	2,441	*	*	*	2,394
All	1,614	1,784	1,384	1,154	1,633	1,703	2,095	1,773	1,204	1,791	1,661	1,974	1,629	1,185	1,720
ALL															
0-19	1,270	1,747	*	1,155	1,397	1,603	2,049	*	*	1,812	1,447	1,909	*	2,086	1,616
20-29	1,497	1,476	1,304	519	1,431	1,647	2,170	869	1,219	1,815	1,582	1,886	1,011	947	1,654
30-39	1,888	1,931	1,142	874	1,836	1,762	2,224	1,818	1,193	1,932	1,822	2,103	1,581	1,027	1,889
40-49	1,827	1,517	1,485	964	1,672	1,967	1,896	1,951	673	1,852	1,894	1,720	1,802	773	1,764
50-59	1,767	1,909	1,915	1,214	1,789	2,062	2,156	1,965	1,305	2,059	1,905	2,049	1,940	1,263	1,925
60-64	2,073	2,174	2,516	1,724	2,091	2,195	2,193	3,216	775	2,156	2,132	2,186	2,818	1,224	2,125
65-69	1,876	1,980	1,466	1,464	1,876	1,914	2,272	2,093	1,360	1,974	1,893	2,157	1,798	1,393	1,925
70-79	1,919	1,919	2,411	1,294	1,899	2,148	2,703	3,369	1,919	2,253	2,011	2,374	2,945	1,575	2,051
80+	1,970	3,560	*	1,233	2,006	2,415	2,544	*	3,111	2,467	2,140	2,904	*	2,319	2,195
All	1,861	1,808	1,759	1,154	1,819	2,007	2,171	2,052	1,285	2,026	1,928	2,017	1,928	1,227	1,922

Includes all patients who have reached day 91 of ESRD by December 31 of each calendar year.

Patient age is determined on January 1 of each calendar year.

* Values for cells with fewer than 10 patients are suppressed.

." Zero patients in this cell.

Table E.14

Total Admissions: CAPD/CCPD Patients, 1998-2000 Combined

per 1,000 patient years, period prevalent patients, by primary diagnosis & age; grouped by gender & race

DIABETES	Male					Female					All				
	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All
0-19
20-29	2,609	3,578	*	*	3,007	2,435	3,934	*	*	2,891	2,500	3,790	3,051	*	2,935
30-39	2,795	2,455	1,029	*	2,695	2,685	2,948	2,402	3,774	2,762	2,748	2,738	1,682	3,102	2,726
40-49	2,289	2,286	2,700	1,726	2,289	2,659	3,069	2,924	1,143	2,740	2,441	2,712	2,831	1,371	2,492
50-59	2,343	2,465	2,195	1,943	2,350	2,906	2,775	2,378	2,221	2,812	2,585	2,648	2,299	2,059	2,573
60-64	2,530	2,414	2,451	2,079	2,488	2,738	2,755	2,955	1,663	2,702	2,629	2,614	2,751	1,827	2,598
65-69	2,395	2,449	1,358	1,013	2,326	2,530	2,514	2,038	2,171	2,495	2,458	2,490	1,737	1,680	2,412
70-79	2,456	2,170	2,271	1,632	2,392	2,620	3,016	2,583	2,127	2,690	2,527	2,716	2,463	1,910	2,534
80+	2,563	4,652	.	1,284	2,651	2,558	2,900	*	2,115	2,585	2,561	3,299	*	1,888	2,614
All	2,443	2,425	2,139	1,689	2,411	2,685	2,854	2,555	2,057	2,704	2,550	2,682	2,378	1,894	2,554
HYPERTENSION															
0-19	*	*	.	*	1,688	*	*	.	*	1,504	1,301	1,404	.	*	1,580
20-29	860	1,471	*	596	1,207	952	1,756	*	571	1,360	911	1,609	1,623	583	1,287
30-39	1,498	1,731	*	1,516	1,646	1,530	1,764	732	1,391	1,658	1,512	1,746	678	1,440	1,651
40-49	1,385	1,477	1,784	1,460	1,451	1,425	1,519	1,469	1,209	1,480	1,400	1,496	1,614	1,345	1,464
50-59	1,695	1,815	2,015	835	1,736	1,704	1,995	*	1,185	1,845	1,699	1,904	1,698	1,041	1,786
60-64	1,990	1,919	*	1,169	1,957	2,083	1,827	*	481	1,890	2,031	1,860	3,691	814	1,922
65-69	1,803	2,163	3,447	1,706	1,889	1,919	2,174	*	818	1,948	1,853	2,169	3,658	1,146	1,917
70-79	1,923	2,000	*	1,408	1,908	2,182	2,275	2,117	1,749	2,183	2,026	2,144	1,720	1,541	2,023
80+	1,832	3,371	*	1,805	1,910	2,148	2,291	*	1,651	2,132	1,957	2,705	*	1,725	2,003
All	1,783	1,746	2,192	1,325	1,756	1,936	1,864	1,605	1,223	1,866	1,846	1,805	1,907	1,273	1,805
GLOMERULONEPHRITIS															
0-19	1,504	1,453	*	739	1,430	1,563	2,098	*	*	1,716	1,539	1,821	1,743	720	1,595
20-29	1,458	1,576	1,688	653	1,449	1,552	1,996	659	550	1,648	1,511	1,822	1,060	601	1,562
30-39	1,189	1,810	*	651	1,345	1,433	1,504	957	729	1,403	1,315	1,615	1,006	687	1,378
40-49	1,352	1,457	1,100	525	1,328	1,299	1,482	1,753	578	1,291	1,327	1,471	1,411	560	1,309
50-59	1,439	1,655	835	956	1,456	1,561	1,664	*	633	1,513	1,496	1,660	1,097	763	1,484
60-64	1,703	1,843	*	1,472	1,687	1,590	1,673	*	*	1,644	1,656	1,727	1,218	1,634	1,666
65-69	1,669	2,105	*	1,820	1,712	1,702	1,804	*	2,220	1,741	1,683	1,903	*	2,003	1,725
70-79	1,756	1,549	*	738	1,726	1,974	1,743	*	1,115	1,914	1,836	1,657	2,247	894	1,798
80+	1,842	2,069	*	*	1,867	2,005	*	*	*	1,929	1,904	1,694	*	*	1,892
All	1,527	1,628	1,326	813	1,509	1,577	1,651	1,222	755	1,539	1,550	1,642	1,260	781	1,524
OTHER															
0-19	1,964	2,300	.	1,795	2,054	1,766	2,669	*	2,073	2,069	1,871	2,472	*	1,924	2,061
20-29	1,386	1,848	*	753	1,519	1,998	2,209	*	1,303	2,008	1,739	2,067	652	1,157	1,811
30-39	1,544	1,940	1,020	1,446	1,667	1,536	2,334	1,607	1,478	1,842	1,539	2,194	1,373	1,466	1,776
40-49	1,358	1,668	1,834	1,177	1,471	1,681	2,036	1,375	829	1,759	1,546	1,890	1,558	949	1,642
50-59	1,521	1,911	1,515	1,292	1,604	1,647	1,697	2,859	1,102	1,648	1,594	1,774	2,035	1,158	1,630
60-64	1,534	2,173	*	*	1,626	1,796	2,198	*	841	1,837	1,693	2,189	1,377	829	1,754
65-69	1,559	1,953	.	1,561	1,606	1,802	2,180	3,576	1,123	1,843	1,684	2,070	3,576	1,294	1,729
70-79	1,857	1,957	2,897	1,062	1,841	1,846	2,786	1,903	881	1,898	1,853	2,401	2,234	971	1,866
80+	1,986	3,112	*	*	1,940	2,319	2,352	.	*	2,292	2,118	2,624	*	376	2,081
All	1,623	1,894	1,546	1,215	1,668	1,754	2,136	1,877	1,138	1,830	1,693	2,040	1,745	1,167	1,758
ALL															
0-19	1,850	2,027	*	1,377	1,877	1,675	2,457	2,745	1,875	1,948	1,762	2,249	2,525	1,610	1,913
20-29	1,495	1,772	1,875	836	1,574	1,806	2,177	1,099	1,025	1,886	1,674	2,004	1,336	947	1,754
30-39	1,958	1,905	1,034	1,085	1,888	1,850	2,038	1,314	1,376	1,888	1,903	1,982	1,229	1,250	1,888
40-49	1,744	1,640	1,969	1,059	1,683	1,877	1,923	2,082	800	1,834	1,806	1,788	2,032	901	1,758
50-59	1,896	2,000	1,956	1,363	1,909	2,107	2,161	2,270	1,232	2,092	1,996	2,090	2,113	1,290	2,001
60-64	2,122	2,171	2,256	1,579	2,117	2,239	2,230	2,904	1,258	2,210	2,179	2,208	2,603	1,398	2,166
65-69	1,957	2,249	1,946	1,366	1,981	2,101	2,302	2,485	1,666	2,132	2,023	2,281	2,251	1,539	2,055
70-79	2,039	2,015	2,344	1,317	2,012	2,225	2,639	2,266	1,641	2,276	2,115	2,376	2,297	1,470	2,127
80+	1,969	3,369	*	1,380	2,015	2,245	2,457	*	1,713	2,240	2,083	2,783	2,067	1,568	2,113
All	1,931	1,916	1,921	1,247	1,901	2,059	2,157	2,055	1,275	2,052	1,990	2,052	1,998	1,263	1,976

Includes all patients who have reached day 91 of ESRD by December 31 of each calendar year.

Patient age is determined on January 1 of each calendar year.

* Values for cells with fewer than 10 patients are suppressed.

." Zero patients in this cell.

Table E.15

Total Admissions: Transplant Patients, 2000

per 1,000 patient years, period prevalent patients, by primary diagnosis & age; grouped by gender & race

DIABETES	Male					Female					All				
	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All
0-19	*	*	.	.	.	*	*	.	.	.	*
20-29	1,237	1,172	.	*	1,210	2,159	1,279	.	*	1,869	1,690	1,240	.	*	1,557
30-39	1,087	1,183	*	*	1,110	1,350	1,327	*	621	1,348	1,193	1,251	2,624	520	1,209
40-49	939	1,282	764	261	974	998	1,638	*	1,275	1,133	961	1,429	1,217	702	1,033
50-59	898	1,261	1,045	1,056	994	1,207	1,054	1,156	1,086	1,154	1,007	1,169	1,094	1,067	1,055
60-64	1,321	1,160	1,122	604	1,243	1,249	1,119	2,086	750	1,203	1,298	1,141	1,420	669	1,228
65-69	1,157	1,241	*	809	1,172	1,082	1,350	*	957	1,127	1,128	1,281	1,265	873	1,155
70-79	1,347	1,091	*	*	1,261	1,883	1,829	*	*	1,773	1,474	1,493	*	*	1,425
80+	*	.	.	.	*	*	*	.	.	.	*
All	1,037	1,230	1,184	669	1,069	1,234	1,276	1,545	938	1,244	1,110	1,251	1,322	784	1,137
HYPERTENSION															
0-19	*	*	.	.	*	*	.	*	*	*	*	*	*	*	708
20-29	205	557	*	850	455	1,018	1,325	*	*	1,191	496	777	*	978	684
30-39	468	762	*	461	635	557	820	*	203	662	501	779	*	368	644
40-49	588	920	349	454	772	401	734	*	156	569	526	865	553	334	708
50-59	552	648	*	309	600	830	1,187	*	642	994	648	834	821	494	741
60-64	929	1,126	*	1,243	1,027	1,053	710	.	*	881	976	955	*	1,058	971
65-69	593	1,125	.	460	722	684	695	.	*	693	622	933	.	568	711
70-79	756	1,059	.	*	783	1,299	316	.	*	1,017	924	711	.	*	862
80+	*	*	.	.	*	*	.	.	.	*	*	*	.	.	*
All	599	807	537	539	701	756	908	885	487	813	654	840	654	517	739
GLOMERULONEPHRITIS															
0-19	1,000	1,914	*	*	1,280	891	2,180	*	*	1,148	943	2,009	*	609	1,217
20-29	443	924	*	165	570	1,021	1,055	*	469	977	665	975	0	290	729
30-39	500	640	726	282	529	569	901	*	327	633	525	740	496	304	569
40-49	495	712	448	315	529	571	641	851	314	559	520	683	626	315	540
50-59	622	699	*	466	623	607	806	*	347	616	616	738	98	410	620
60-64	507	919	*	*	551	1,103	981	*	*	1,013	698	938	*	174	703
65-69	700	1,761	*	*	801	764	1,095	*	*	821	724	1,482	*	*	809
70-79	771	*	*	*	822	907	*	.	*	872	807	1,562	*	*	836
80+	*	.	.	.	*	*	.	.	.	*	*	.	.	.	*
All	554	846	379	305	606	715	925	367	376	729	613	876	373	340	652
OTHER															
0-19	745	1,178	*	125	835	869	1,723	*	1,270	1,030	796	1,361	*	746	913
20-29	466	1,103	*	413	581	913	917	*	552	905	672	996	*	488	740
30-39	582	633	*	73	575	798	900	*	344	804	689	791	*	243	694
40-49	512	420	*	181	494	611	901	*	68	635	557	681	631	99	562
50-59	625	813	*	906	668	592	761	296	918	631	609	788	423	913	650
60-64	672	1,034	*	*	739	710	848	*	*	732	690	951	*	1,008	736
65-69	841	931	*	*	865	673	1,235	.	*	742	766	1,080	*	726	810
70-79	871	464	.	.	846	924	*	.	*	848	888	398	.	*	847
80+	*	*	.	.	*	*	.	.	.	*	*	.	.	.	*
All	616	807	950	474	648	718	944	576	497	753	663	877	752	488	698
ALL															
0-19	798	1,366	*	337	934	863	1,820	*	1,062	1,054	827	1,524	650	702	985
20-29	516	880	400	356	612	1,110	1,066	795	550	1,065	772	962	609	442	809
30-39	718	769	998	292	721	898	968	1,050	347	892	794	853	1,018	320	793
40-49	662	850	654	324	697	709	927	1,043	294	740	680	881	796	308	714
50-59	706	845	903	657	747	783	999	824	688	838	737	907	867	673	784
60-64	889	1,097	1,017	770	935	964	938	1,719	610	952	918	1,029	1,244	704	942
65-69	842	1,224	1,721	616	914	798	1,072	*	976	858	825	1,160	1,182	759	892
70-79	902	1,081	*	*	905	1,167	931	*	*	1,092	979	1,011	*	241	965
80+	1,453	*	.	.	1,505	*	.	.	.	*	1,231	*	.	.	1,311
All	720	902	874	460	759	853	1,010	941	509	877	773	946	902	484	807

Includes all patients who have reached day 91 of ESRD by December 31 of each calendar year.

Patient age is determined on January 1 of each calendar year.

First three years after transplant

* Values for cells with fewer than 10 patients are suppressed.

." Zero patients in this cell.

Table E.16

Total Admissions: Transplant Patients, 1998-2000 Combined

per 1,000 patient years, period prevalent patients, by primary diagnosis & age; grouped by gender & race

DIABETES	Male					Female					All				
	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All
0-19	*	*	.	.	*	*	.	.	.	*	*	.	.	.	*
20-29	1,320	1,665	*	*	1,386	1,587	1,355	*	*	1,521	1,453	1,483	*	*	1,456
30-39	1,101	1,293	1,351	327	1,123	1,306	1,410	3,182	1,087	1,341	1,187	1,349	2,166	750	1,217
40-49	940	1,444	1,157	317	1,005	1,181	1,561	1,079	1,079	1,239	1,029	1,491	1,124	674	1,093
50-59	965	1,218	1,062	782	1,026	1,171	1,325	1,340	1,157	1,232	1,036	1,267	1,186	910	1,104
60-64	1,123	1,195	890	512	1,109	1,284	1,286	1,080	591	1,240	1,178	1,237	973	548	1,160
65-69	947	1,203	1,981	731	1,022	1,257	1,530	*	890	1,302	1,058	1,338	1,575	800	1,127
70-79	1,149	1,209	*	*	1,122	1,292	1,684	*	*	1,400	1,183	1,421	*	295	1,203
80+	*	.	.	.	*	*	.	.	.	*
All	1,022	1,290	1,132	565	1,066	1,252	1,399	1,418	977	1,285	1,109	1,340	1,256	741	1,152
HYPERTENSION															
0-19	735	174	.	.	464	898	*	*	*	1,318	820	594	*	*	889
20-29	468	675	*	511	586	845	1,097	*	*	983	597	812	682	555	718
30-39	557	770	1,053	435	673	656	860	*	366	744	590	797	916	411	695
40-49	626	844	734	395	747	570	862	1,257	375	720	607	850	861	386	739
50-59	598	710	952	553	659	735	989	1,101	483	848	644	800	1,009	520	723
60-64	833	1,010	*	736	896	868	846	*	545	841	845	946	*	684	876
65-69	839	1,320	*	656	954	860	975	.	837	902	846	1,166	*	718	935
70-79	910	1,216	.	1,101	972	1,302	764	.	*	1,114	1,021	1,014	.	947	1,017
80+	*	*	.	.	671	*	.	.	.	*	619	*	.	.	619
All	674	815	833	543	740	762	919	1,165	464	826	703	849	959	512	768
GLOMERULONEPHRITIS															
0-19	888	1,183	*	745	977	867	1,881	*	731	1,088	877	1,452	254	739	1,030
20-29	430	758	517	469	530	1,000	1,043	655	513	974	651	867	578	488	703
30-39	440	599	527	285	473	571	823	577	310	617	486	687	547	298	527
40-49	475	754	434	320	527	578	702	931	393	591	511	733	657	362	552
50-59	564	728	564	313	582	614	933	629	337	648	582	804	593	326	607
60-64	645	864	798	416	669	802	888	*	524	795	698	873	819	468	713
65-69	773	960	*	249	777	727	1,225	*	813	757	1,065	*	684	790	
70-79	824	1,329	*	*	833	865	441	.	*	811	834	960	*	827	
80+	*	.	.	.	*	*	.	.	.	*	482	.	.	482	
All	535	754	494	357	574	697	930	662	413	727	594	823	566	385	632
OTHER															
0-19	786	1,184	738	545	861	900	1,563	2,262	1,241	1,042	832	1,312	1,510	836	932
20-29	551	835	449	442	596	908	1,088	1,146	517	930	718	965	805	480	756
30-39	580	744	666	137	600	776	893	1,281	516	798	675	829	1,029	377	701
40-49	536	738	832	387	568	605	938	292	378	664	566	844	535	381	612
50-59	577	823	853	833	627	638	807	389	682	666	607	815	534	744	646
60-64	680	930	644	689	723	692	1,038	836	914	751	686	976	741	794	736
65-69	856	997	*	779	899	810	1,183	*	180	850	836	1,073	4,522	409	877
70-79	886	1,123	.	*	909	1,047	768	.	*	1,033	942	957	.	1,594	954
80+	741	*	.	.	790	*	.	.	.	*	636	*	.	.	698
All	625	862	905	502	665	737	981	1,008	582	781	676	921	962	548	719
ALL															
0-19	805	1,152	597	608	882	887	1,683	1,665	1,042	1,060	841	1,341	1,242	798	956
20-29	577	816	440	464	638	1,027	1,108	955	546	1,025	772	941	715	499	805
30-39	710	794	853	294	719	900	966	1,518	461	904	789	867	1,155	380	797
40-49	667	900	815	352	718	782	963	851	452	808	710	925	830	406	753
50-59	698	870	964	596	747	774	1,054	1,059	593	848	728	944	1,009	594	788
60-64	832	1,040	852	592	871	887	1,063	976	626	923	853	1,049	903	606	892
65-69	855	1,168	1,995	626	918	901	1,226	1,554	729	969	872	1,192	1,859	669	938
70-79	922	1,212	*	782	952	1,113	1,027	*	847	1,084	977	1,129	*	806	994
80+	1,134	*	.	.	1,050	355	.	.	.	355	950	*	.	.	915
All	717	902	895	468	757	862	1,051	1,115	546	898	775	962	994	506	814

Includes all patients who have reached day 91 of ESRD by December 31 of each calendar year.

Patient age is determined on January 1 of each calendar year.

First three years after transplant.

* Values for cells with fewer than 10 patients are suppressed.

." Zero patients in this cell.

Table E.17

Hospital Days: ESRD Patients, 2000

per patient year, period prevalent patients, by primary diagnosis & age; grouped by gender & race

DIABETES	Male					Female					All				
	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All
0-19	*	*	.	.	*	*	*	.	.	*	*	*	*	.	*
20-29	14.2	18.2	*	*	15.4	18.0	19.5	14.5	*	18.5	16.1	19.0	13.0	8.2	17.1
30-39	14.9	16.3	19.3	10.5	15.2	16.6	19.0	20.2	10.2	17.4	15.5	17.7	19.8	10.3	16.1
40-49	14.5	15.6	10.5	12.7	14.6	18.1	17.8	13.2	15.6	17.7	15.9	16.7	11.7	13.9	15.9
50-59	15.2	15.3	11.9	11.8	15.0	17.8	17.5	14.2	14.5	17.4	16.4	16.5	13.1	13.0	16.1
60-64	15.9	14.9	12.5	15.8	15.4	18.1	17.0	15.8	12.9	17.3	17.0	16.1	14.2	14.2	16.4
65-69	17.1	16.3	15.8	12.8	16.7	18.1	18.0	18.2	12.7	17.8	17.6	17.4	17.4	12.7	17.3
70-79	17.4	16.7	15.7	15.4	17.1	18.5	19.1	16.0	16.5	18.6	18.0	18.4	15.9	16.1	18.0
80 +	17.1	18.7	16.5	14.8	17.3	18.6	19.4	14.8	15.5	18.7	17.9	19.2	15.4	15.2	18.1
All	16.1	15.9	13.2	13.6	15.9	18.1	18.1	15.7	14.6	17.9	17.1	17.2	14.6	14.2	17.0
HYPERTENSION															
0-19	*	10.6	*	*	8.5	2.5	7.4	*	*	8.4	4.1	8.8	*	*	8.4
20-29	4.6	5.5	*	4.0	5.2	8.5	8.6	14.7	2.7	8.6	6.1	6.5	10.3	3.6	6.4
30-39	8.4	8.5	5.5	7.8	8.4	9.2	9.9	*	6.3	9.7	8.7	9.0	6.3	7.3	8.9
40-49	8.8	8.6	10.9	5.0	8.6	10.7	10.4	9.3	7.9	10.4	9.4	9.2	10.3	6.3	9.2
50-59	10.5	9.8	12.3	7.9	10.0	12.5	12.6	7.4	10.0	12.5	11.2	10.9	10.6	8.9	10.9
60-64	13.0	12.1	9.7	10.2	12.3	14.7	13.3	23.5	9.7	13.8	13.7	12.6	16.6	10.0	13.0
65-69	11.7	12.3	18.5	8.3	11.9	15.0	15.3	14.4	7.4	14.9	13.1	13.8	16.3	7.8	13.3
70-79	13.3	14.3	16.1	12.3	13.5	16.2	16.8	13.4	9.7	16.2	14.5	15.8	14.4	11.0	14.8
80 +	13.8	16.4	16.3	10.7	14.2	14.9	17.2	12.9	13.9	15.7	14.3	17.0	14.0	12.4	14.9
All	12.3	10.5	12.0	9.3	11.3	14.7	13.9	13.1	9.8	14.1	13.3	12.0	12.5	9.5	12.5
GLOMERULONEPHRITIS															
0-19	9.9	8.0	*	6.7	8.9	8.2	12.2	*	4.1	9.4	9.0	10.0	*	5.6	9.2
20-29	5.9	6.7	2.5	4.2	6.1	7.8	9.5	6.5	4.3	8.3	6.7	7.9	4.5	4.2	7.0
30-39	5.2	7.2	7.8	6.8	6.1	7.1	9.5	8.6	5.3	8.1	5.9	8.2	8.2	6.2	6.9
40-49	7.9	9.4	5.5	5.9	8.4	8.9	10.8	8.8	5.1	9.3	8.2	9.9	6.8	5.4	8.7
50-59	8.4	9.5	8.2	7.1	8.7	10.7	11.2	17.4	5.1	10.6	9.3	10.1	12.1	6.1	9.5
60-64	9.3	10.6	3.7	6.4	9.4	12.1	11.9	14.7	5.9	11.8	10.4	11.3	9.4	6.2	10.4
65-69	10.3	11.6	6.5	10.8	10.6	11.9	14.6	10.7	9.6	12.4	11.0	13.1	8.6	10.1	11.4
70-79	11.8	11.1	10.3	10.1	11.6	15.3	15.5	11.3	13.0	15.1	13.1	13.5	10.8	11.5	13.1
80 +	14.0	13.9	*	10.4	13.9	14.8	17.3	17.8	7.8	14.8	14.3	15.7	18.6	8.9	14.3
All	9.0	8.9	6.6	7.1	8.8	11.0	11.3	10.8	6.5	10.8	9.7	9.9	8.6	6.8	9.6
OTHER															
0-19	6.9	10.7	4.1	4.5	7.9	7.4	18.0	*	22.5	10.8	7.1	13.7	3.5	13.6	9.1
20-29	6.4	8.7	9.5	4.3	7.1	9.9	12.1	5.8	8.8	10.6	8.0	10.5	7.4	6.9	8.8
30-39	7.2	10.1	15.9	4.6	8.4	9.3	13.3	10.6	8.0	10.9	8.2	11.7	12.9	6.4	9.6
40-49	8.2	10.6	8.8	4.8	9.1	11.1	12.2	6.2	7.8	11.3	9.5	11.3	7.7	6.7	10.1
50-59	10.2	10.9	11.1	7.4	10.4	11.1	13.0	7.2	8.6	11.6	10.7	11.9	9.2	8.1	11.0
60-64	11.1	14.4	16.1	14.6	12.2	12.8	15.2	2.2	7.9	13.3	11.9	14.8	10.0	10.8	12.8
65-69	12.6	14.3	21.1	10.8	13.0	13.9	14.8	15.2	13.5	14.1	13.2	14.5	18.2	12.2	13.5
70-79	13.1	14.4	8.0	8.8	13.2	14.6	17.7	12.4	11.5	15.1	13.8	16.1	10.4	10.3	14.1
80 +	14.8	15.4	12.3	8.2	14.7	16.1	20.7	7.5	8.9	16.7	15.4	18.1	9.9	8.5	15.6
All	10.7	11.6	11.5	7.4	10.8	12.3	14.1	8.2	9.5	12.8	11.4	12.8	9.9	8.6	11.7
ALL															
0-19	7.6	10.0	3.9	5.5	8.2	7.5	15.3	8.3	15.7	10.3	7.6	12.4	5.9	10.5	9.2
20-29	6.8	7.5	4.8	4.2	7.0	10.1	11.5	8.9	6.5	10.5	8.3	9.3	7.2	5.3	8.6
30-39	9.3	9.5	12.7	6.8	9.4	10.8	12.4	12.7	7.2	11.5	9.9	10.8	12.7	7.0	10.2
40-49	10.5	10.3	9.4	7.1	10.3	13.1	12.8	10.9	8.0	12.6	11.5	11.3	10.0	7.6	11.2
50-59	12.3	11.7	11.6	9.3	11.9	14.3	14.8	13.4	10.1	14.3	13.1	13.1	12.5	9.7	13.0
60-64	13.5	13.5	12.0	12.6	13.4	15.9	15.5	15.7	10.7	15.5	14.6	14.6	13.9	11.7	14.5
65-69	14.1	14.3	15.7	11.2	14.1	16.2	16.7	17.4	11.2	16.2	15.1	15.7	16.8	11.2	15.2
70-79	14.4	15.1	14.4	12.7	14.5	16.8	18.0	15.1	13.6	17.1	15.5	16.9	14.9	13.2	15.9
80 +	14.7	16.7	15.8	11.5	14.9	16.1	18.4	13.7	13.2	16.6	15.3	17.8	14.5	12.5	15.8
All	12.7	12.0	11.9	9.9	12.3	15.0	15.4	14.1	10.9	15.0	13.7	13.7	13.1	10.4	13.6

Includes all patients who have reached day 91 of ESRD by December 31 of each calendar year.

Patient age is determined on January 1 of each calendar year.

* Values for cells with fewer than 10 patients are suppressed.

." Zero patients in this cell.

Table E.18
Hospital Days: ESRD Patients, 1998-2000 Combined
per patient year, period prevalent patients, by primary diagnosis & age; grouped by gender & race

DIABETES	Male					Female					All				
	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All
0-19	*	*	.	.	21.8	*	23.2	.	.	31.4	27.8	28.4	.	.	28.1
20-29	13.6	18.4	16.9	4.7	15.1	17.5	21.9	11.3	9.5	19.1	15.6	20.5	12.3	7.4	17.3
30-39	14.8	16.7	12.9	7.9	15.1	16.6	19.3	20.8	14.6	17.5	15.5	18.0	16.8	11.4	16.1
40-49	14.8	15.6	12.5	10.8	14.9	17.3	18.2	13.2	14.0	17.4	15.8	16.9	12.8	12.2	16.0
50-59	15.5	15.4	13.3	12.0	15.2	18.3	17.4	14.4	14.6	17.6	16.7	16.5	13.8	13.1	16.4
60-64	16.5	15.6	14.3	12.8	16.0	18.5	17.3	14.6	14.4	17.7	17.5	16.7	14.5	13.7	16.9
65-69	17.4	16.7	14.9	13.1	16.9	18.6	18.0	16.1	15.3	18.1	18.1	17.5	15.7	14.3	17.6
70-79	17.9	16.7	15.1	14.2	17.4	18.8	19.0	15.4	14.9	18.6	18.4	18.3	15.3	14.6	18.1
80+	18.0	18.4	17.2	12.5	17.8	19.7	20.1	16.7	15.2	19.6	18.9	19.6	16.9	14.0	18.8
All	16.4	16.1	13.8	12.6	16.1	18.4	18.2	15.1	14.8	18.1	17.4	17.4	14.5	13.8	17.2
HYPERTENSION															
0-19	5.7	4.7	*	*	5.0	4.4	10.9	*	*	9.6	5.0	7.4	*	*	7.2
20-29	5.2	6.0	6.6	4.1	5.8	6.9	8.2	11.8	3.3	7.8	5.9	6.7	9.9	3.9	6.5
30-39	7.5	8.4	9.6	6.7	8.2	8.7	9.6	10.9	5.4	9.3	7.9	8.8	10.0	6.3	8.5
40-49	8.5	8.9	9.6	6.1	8.8	10.2	10.4	8.8	10.1	10.3	9.1	9.4	9.3	7.8	9.3
50-59	10.4	9.9	12.9	8.0	10.0	13.1	12.6	9.0	10.0	12.6	11.4	10.9	11.4	8.9	11.0
60-64	12.7	11.7	10.7	8.3	12.0	14.9	12.8	18.0	9.8	13.5	13.6	12.3	14.7	8.9	12.6
65-69	12.2	13.1	14.9	9.2	12.5	15.5	15.1	17.2	9.0	15.1	13.6	14.1	16.2	9.1	13.7
70-79	13.6	14.2	14.3	11.1	13.7	16.1	16.9	13.3	9.3	16.2	14.6	15.8	13.7	10.2	14.9
80+	14.1	16.2	16.6	10.8	14.4	16.1	18.1	12.7	10.8	16.5	15.0	17.4	14.0	10.8	15.5
All	12.4	10.6	11.9	9.0	11.4	15.0	13.9	12.7	9.5	14.2	13.4	12.1	12.3	9.2	12.6
GLOMERULONEPHRITIS															
0-19	8.3	8.7	5.8	7.3	8.4	8.3	12.3	7.1	4.0	9.5	8.3	10.3	6.7	5.8	8.9
20-29	5.7	6.5	6.3	4.8	6.0	8.4	8.9	8.4	4.8	8.4	6.8	7.5	7.3	4.8	7.0
30-39	5.6	7.7	6.3	5.5	6.4	8.2	9.3	6.6	5.1	8.5	6.6	8.4	6.4	5.3	7.2
40-49	7.7	9.7	6.4	5.7	8.4	8.5	10.7	9.1	5.1	9.1	8.0	10.1	7.4	5.4	8.7
50-59	8.6	9.9	8.7	7.2	9.0	11.1	11.3	13.6	6.7	10.9	9.6	10.5	10.7	6.9	9.8
60-64	10.3	10.5	5.0	8.6	10.2	12.0	11.8	17.7	11.6	12.0	10.9	11.1	11.1	9.8	11.0
65-69	11.5	12.9	10.5	14.3	11.9	12.0	14.2	6.3	9.9	12.4	11.7	13.6	8.3	11.9	12.1
70-79	11.9	11.6	14.1	8.6	11.7	15.0	14.7	7.9	11.6	14.7	13.1	13.2	11.2	10.1	13.0
80+	13.7	16.3	16.3	11.6	13.9	15.2	15.8	12.1	11.7	15.1	14.3	16.1	13.7	11.7	14.4
All	9.1	9.3	7.7	7.0	9.1	11.1	11.1	9.4	7.0	10.8	9.9	10.0	8.5	7.0	9.8
OTHER															
0-19	7.6	11.4	6.3	7.7	8.6	8.1	16.9	13.5	11.4	10.6	7.8	13.7	9.9	9.4	9.5
20-29	6.8	8.8	7.6	5.6	7.4	10.1	13.5	11.0	9.7	11.4	8.4	11.2	9.4	7.9	9.4
30-39	7.7	10.4	17.3	7.8	8.8	9.7	13.0	9.6	8.4	11.0	8.6	11.7	13.2	8.1	9.9
40-49	8.3	11.0	8.5	6.3	9.4	10.5	13.2	6.9	8.9	11.5	9.3	12.0	7.8	7.8	10.4
50-59	9.9	10.9	10.0	8.9	10.2	11.5	13.1	11.8	9.5	12.0	10.7	12.0	10.9	9.2	11.1
60-64	11.2	13.4	11.5	10.9	11.9	13.0	15.0	7.0	10.2	13.5	12.1	14.3	9.5	10.5	12.7
65-69	12.7	14.4	17.4	11.2	13.1	14.4	15.8	17.5	12.0	14.7	13.5	15.2	17.5	11.7	13.9
70-79	13.2	13.7	16.1	9.3	13.3	15.1	18.1	12.8	11.5	15.6	14.1	16.0	14.3	10.6	14.4
80+	14.6	16.8	10.3	11.2	14.8	15.8	20.0	16.4	12.7	16.6	15.1	18.5	13.3	11.9	15.6
All	10.7	11.7	11.8	8.5	11.0	12.5	14.6	10.9	10.1	13.1	11.5	13.1	11.4	9.4	12.0
ALL															
0-19	7.7	10.2	6.0	7.5	8.5	8.2	14.9	11.4	9.1	10.4	7.9	12.3	9.1	8.3	9.3
20-29	7.0	7.7	7.2	5.0	7.2	10.3	11.9	10.3	7.0	10.8	8.5	9.6	8.9	6.0	8.8
30-39	9.4	9.7	11.3	6.5	9.5	11.3	12.2	11.9	7.7	11.6	10.2	10.8	11.6	7.1	10.4
40-49	10.6	10.6	10.2	7.0	10.5	12.4	13.1	11.0	8.4	12.5	11.3	11.6	10.5	7.7	11.3
50-59	12.3	11.8	12.5	9.6	12.0	14.7	14.8	13.7	10.7	14.6	13.3	13.2	13.1	10.1	13.1
60-64	13.8	13.5	13.1	10.7	13.6	16.1	15.5	14.6	12.6	15.7	14.9	14.6	13.9	11.6	14.6
65-69	14.4	14.8	14.7	12.0	14.5	16.6	16.7	15.7	12.8	16.5	15.5	15.9	15.3	12.4	15.5
70-79	14.7	14.9	15.0	11.7	14.6	17.0	18.0	14.5	12.6	17.1	15.7	16.8	14.7	12.2	15.9
80+	14.8	16.9	15.3	11.5	15.1	16.8	18.9	15.3	12.6	17.3	15.7	18.2	15.3	12.1	16.2
All	12.8	12.1	12.4	9.6	12.4	15.2	15.5	13.7	11.0	15.1	13.9	13.8	13.1	10.3	13.7

Includes all patients who have reached day 91 of ESRD by December 31 of each calendar year.
 Patient age is determined on January 1 of each calendar year.
 * Values for cells with fewer than 10 patients are suppressed.
 "." Zero patients in this cell.

Table E.19

Hospital Days: Dialysis Patients, 2000

per patient year, period prevalent patients, by primary diagnosis & age; grouped by gender & race

DIABETES	Male					Female					All				
	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All
0-19	*	*	.	.	*	*	*	.	.	*	*	*	.	.	*
20-29	15.9	19.9	*	*	17.3	20.8	21.0	14.8	*	20.4	18.4	20.6	13.1	6.7	19.0
30-39	17.1	17.1	17.7	12.2	17.0	19.1	19.2	20.1	11.7	19.0	17.8	18.2	18.8	12.0	17.8
40-49	16.1	15.7	10.9	13.5	15.7	20.4	18.1	11.8	15.9	18.8	17.8	16.9	11.3	14.5	17.0
50-59	16.0	15.3	12.3	11.3	15.4	18.5	17.6	14.5	14.9	17.7	17.1	16.6	13.4	12.9	16.6
60-64	16.1	14.9	12.6	16.0	15.5	18.3	17.2	16.0	13.6	17.6	17.2	16.3	14.4	14.7	16.6
65-69	17.4	16.6	16.1	13.2	16.9	18.0	18.0	18.4	12.7	17.8	17.7	17.5	17.6	12.9	17.5
70-79	17.5	16.6	15.8	15.3	17.1	18.5	19.1	16.1	16.5	18.6	18.0	18.3	16.0	16.1	18.0
80 +	17.1	18.7	16.5	14.8	17.3	18.6	19.4	14.8	15.5	18.7	17.9	19.2	15.4	15.2	18.1
All	16.8	16.0	13.4	13.8	16.3	18.6	18.2	15.7	14.9	18.2	17.7	17.4	14.7	14.4	17.3
HYPERTENSION															
0-19	*	14.0	*	*	10.9	*	8.6	.	*	9.7	4.7	10.7	*	*	10.2
20-29	4.9	5.0	*	2.2	4.9	8.3	8.0	16.5	1.2	8.1	6.2	6.0	11.5	1.8	6.0
30-39	9.1	8.5	5.1	9.1	8.6	10.5	10.1	*	7.6	10.1	9.6	9.0	6.6	8.6	9.1
40-49	9.0	8.4	10.8	5.5	8.5	11.9	10.5	10.1	10.2	10.7	9.9	9.1	10.6	7.6	9.2
50-59	11.3	9.8	11.6	8.4	10.2	13.6	12.7	7.3	12.4	12.9	12.1	10.9	10.1	10.1	11.2
60-64	13.2	12.1	10.1	10.4	12.4	15.6	13.5	22.8	10.7	14.2	14.2	12.8	16.6	10.5	13.2
65-69	12.1	12.1	18.5	8.5	12.0	15.2	15.4	14.4	7.5	15.0	13.4	13.8	16.3	7.9	13.4
70-79	13.4	14.3	16.1	12.4	13.6	16.3	16.9	13.4	9.6	16.3	14.6	15.8	14.4	11.0	14.9
80 +	13.8	16.5	16.3	10.7	14.2	14.9	17.2	12.9	13.9	15.7	14.3	17.0	14.0	12.4	14.9
All	12.6	10.6	12.2	9.9	11.5	15.2	14.0	13.4	10.4	14.4	13.7	12.1	12.7	10.1	12.7
GLOMERULONEPHRITIS															
0-19	9.1	5.9	*	*	7.6	9.3	11.3	*	*	9.8	9.2	8.7	*	5.7	8.7
20-29	6.2	6.4	2.2	2.9	6.0	7.3	9.2	5.3	3.7	8.0	6.7	7.6	3.8	3.3	6.9
30-39	5.3	7.0	7.8	6.9	6.2	7.6	9.4	9.2	4.5	8.4	6.2	8.1	8.5	6.0	7.1
40-49	8.5	9.3	6.0	5.6	8.7	9.7	11.1	8.1	4.9	9.9	8.9	9.9	6.8	5.3	9.1
50-59	8.5	9.6	7.7	6.4	8.8	11.9	11.7	19.0	5.9	11.5	9.9	10.4	12.6	6.1	9.9
60-64	10.3	10.6	2.7	7.4	10.1	12.6	12.1	15.3	7.7	12.3	11.2	11.4	9.6	7.5	11.1
65-69	10.8	11.3	6.6	12.1	10.9	12.6	15.0	10.9	8.6	13.0	11.6	13.1	8.6	10.1	11.9
70-79	11.9	11.0	10.4	10.0	11.7	15.4	15.5	11.3	13.2	15.3	13.3	13.4	10.9	11.6	13.2
80 +	14.0	13.9	*	10.4	13.9	14.8	17.3	17.8	7.8	14.8	14.3	15.7	18.6	8.9	14.3
All	9.7	8.9	6.7	7.2	9.3	11.9	11.6	11.2	6.9	11.5	10.6	10.0	8.9	7.0	10.2
OTHER															
0-19	9.1	13.2	*	3.2	10.3	9.5	18.6	*	*	14.1	9.3	15.7	*	23.0	12.0
20-29	7.5	8.4	11.3	4.3	7.8	11.4	12.9	5.5	10.4	11.9	9.3	10.7	8.0	7.9	9.8
30-39	7.8	10.5	18.3	3.8	9.0	10.1	14.1	11.1	10.1	12.0	8.8	12.3	14.3	7.0	10.5
40-49	9.1	11.0	9.0	5.0	9.9	13.1	12.4	6.3	10.1	12.6	10.9	11.6	7.9	7.9	11.1
50-59	11.3	10.4	11.2	5.9	10.8	12.7	13.3	7.2	9.2	12.7	12.0	11.8	9.3	7.7	11.7
60-64	11.8	14.8	16.7	15.8	13.0	13.7	15.5	2.4	8.5	14.1	12.8	15.2	10.3	11.5	13.5
65-69	12.8	14.4	19.2	11.3	13.2	14.7	15.0	15.2	13.9	14.8	13.7	14.7	17.1	12.7	13.9
70-79	13.2	14.5	8.0	8.6	13.2	14.6	17.8	12.4	11.6	15.2	13.8	16.2	10.4	10.2	14.2
80 +	14.8	15.4	12.3	8.2	14.7	16.1	20.7	7.5	8.9	16.7	15.3	18.1	9.9	8.5	15.6
All	11.6	11.8	11.9	7.3	11.6	13.6	14.6	8.6	10.8	13.8	12.5	13.1	10.3	9.2	12.6
ALL															
0-19	9.1	11.1	*	5.7	9.7	9.3	15.2	*	24.8	12.5	9.2	13.1	3.5	15.3	11.0
20-29	7.6	7.3	5.3	3.3	7.2	10.9	11.7	9.1	6.9	11.1	9.1	9.3	7.5	5.1	9.0
30-39	10.3	9.7	13.2	7.1	9.9	12.0	12.7	13.1	8.3	12.2	11.0	10.9	13.1	7.6	10.9
40-49	11.6	10.3	9.7	7.6	10.7	14.9	13.0	10.2	9.3	13.6	12.9	11.4	9.9	8.5	11.9
50-59	13.2	11.7	11.8	8.9	12.3	15.5	15.0	13.8	11.3	15.1	14.2	13.2	12.8	10.0	13.6
60-64	14.1	13.6	12.1	13.2	13.8	16.5	15.7	15.8	11.7	16.0	15.2	14.7	14.1	12.4	14.9
65-69	14.5	14.3	15.8	11.7	14.4	16.5	16.8	17.6	11.3	16.5	15.5	15.8	17.0	11.5	15.5
70-79	14.5	15.0	14.5	12.7	14.6	16.9	18.1	15.1	13.6	17.1	15.6	16.9	14.9	13.2	15.9
80 +	14.7	16.7	15.8	11.5	14.9	16.1	18.4	13.7	13.2	16.6	15.3	17.8	14.5	12.5	15.8
All	13.5	12.1	12.3	10.3	12.8	15.9	15.7	14.4	11.7	15.6	14.6	14.0	13.4	11.0	14.2

Includes all patients who have reached day 91 of ESRD by December 31 of each calendar year.

Patient age is determined on January 1 of each calendar year.

* Values for cells with fewer than 10 patients are suppressed.

." Zero patients in this cell.

Table E.20
Hospital Days: Dialysis Patients, 1998-2000 Combined
per patient year, period prevalent patients, by primary diagnosis & age; grouped by gender & race

DIABETES	Male					Female					All				
	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All
0-19	*	*	.	.	*	*	24.8	.	.	35.6	*	25.5	.	.	30.8
20-29	14.7	19.9	19.8	5.1	16.6	19.6	23.8	10.7	8.7	21.2	17.2	22.3	12.3	6.9	19.1
30-39	17.1	17.5	12.4	8.9	17.0	20.0	20.3	21.2	15.4	20.0	18.1	18.9	16.8	12.3	18.2
40-49	16.5	15.6	12.6	11.4	15.9	19.2	18.3	13.0	14.6	18.4	17.5	17.0	12.8	12.8	17.0
50-59	16.2	15.5	13.5	11.9	15.6	18.9	17.6	14.6	14.9	18.0	17.4	16.6	14.1	13.2	16.8
60-64	17.0	15.7	14.8	13.3	16.3	18.8	17.4	14.9	15.0	17.9	17.9	16.7	14.8	14.2	17.2
65-69	17.7	16.8	14.9	13.3	17.2	18.7	18.0	16.1	15.4	18.2	18.3	17.6	15.7	14.4	17.8
70-79	17.9	16.7	15.2	14.2	17.4	18.8	19.0	15.4	14.9	18.6	18.4	18.3	15.3	14.6	18.1
80+	18.0	18.4	17.2	12.5	17.8	19.7	20.1	16.7	15.2	19.6	18.9	19.6	16.9	14.0	18.8
All	17.2	16.2	14.0	12.8	16.6	18.9	18.4	15.2	15.0	18.4	18.1	17.5	14.7	14.0	17.6
HYPERTENSION															
0-19	7.5	4.9	*	*	5.6	1.2	11.4	.	*	10.0	4.8	8.0	*	*	7.7
20-29	5.3	5.4	5.9	2.9	5.3	6.8	7.9	13.9	2.7	7.6	5.9	6.2	10.7	2.8	6.1
30-39	8.1	8.4	8.3	7.1	8.3	9.3	9.7	12.7	5.0	9.6	8.5	8.8	9.7	6.4	8.7
40-49	8.7	8.8	9.9	6.3	8.8	11.2	10.5	8.7	12.5	10.6	9.5	9.4	9.5	9.0	9.4
50-59	11.2	9.9	12.8	8.2	10.2	14.0	12.7	9.0	11.4	12.9	12.2	11.0	11.3	9.6	11.2
60-64	13.2	11.6	10.8	8.7	12.1	15.6	12.9	18.2	10.1	13.7	14.2	12.2	14.8	9.3	12.8
65-69	12.4	12.8	15.3	8.7	12.5	15.8	15.1	17.2	9.1	15.2	13.8	14.0	16.3	8.9	13.8
70-79	13.7	14.2	14.3	11.1	13.7	16.2	16.9	13.3	9.2	16.2	14.7	15.8	13.7	10.2	14.9
80+	14.1	16.2	16.6	10.8	14.4	16.1	18.1	12.7	10.8	16.6	15.0	17.4	14.0	10.8	15.5
All	12.8	10.7	12.0	9.3	11.6	15.4	14.1	13.1	9.9	14.5	13.9	12.2	12.5	9.6	12.9
GLOMERULONEPHRITIS															
0-19	8.7	7.3	*	7.7	8.0	9.0	10.3	7.6	1.9	9.2	8.8	8.8	7.1	5.0	8.6
20-29	6.4	6.1	6.1	4.3	6.1	8.6	8.8	7.5	4.9	8.5	7.3	7.3	6.8	4.6	7.1
30-39	6.0	7.6	6.3	5.7	6.7	9.1	9.4	6.9	4.7	9.0	7.2	8.4	6.6	5.3	7.6
40-49	8.4	9.7	6.5	5.7	8.9	9.3	11.2	8.9	5.1	9.8	8.7	10.3	7.3	5.4	9.2
50-59	9.0	10.0	9.0	6.7	9.2	12.5	11.4	15.3	7.6	11.8	10.4	10.5	11.6	7.2	10.3
60-64	11.2	10.4	5.0	9.4	10.8	13.0	12.0	18.3	11.2	12.7	11.9	11.2	12.1	10.1	11.6
65-69	12.1	13.0	11.3	15.9	12.4	14.4	14.4	5.2	9.2	12.7	12.2	13.7	8.1	12.2	12.5
70-79	11.9	11.4	14.5	8.6	11.7	15.2	14.7	7.9	11.7	14.8	13.1	13.2	11.3	10.1	13.0
80+	13.7	16.3	16.3	11.6	13.9	15.2	15.8	12.1	11.7	15.1	14.3	16.1	13.7	11.7	14.4
All	10.0	9.3	8.1	7.3	9.6	12.2	11.3	9.7	7.5	11.6	10.9	10.2	8.8	7.4	10.4
OTHER															
0-19	9.9	12.3	6.3	8.6	10.6	10.2	17.9	13.7	15.4	13.4	10.0	14.9	9.8	12.3	11.8
20-29	7.4	8.8	9.5	5.1	7.9	11.5	14.0	12.7	11.5	12.6	9.3	11.5	11.3	8.9	10.2
30-39	8.3	10.7	18.8	8.8	9.5	11.0	13.6	10.0	9.8	12.1	9.5	12.1	14.3	9.3	10.8
40-49	9.3	11.2	8.9	6.9	10.1	12.3	13.7	7.8	10.2	12.8	10.6	12.3	8.5	8.7	11.3
50-59	11.0	10.6	10.2	7.7	10.7	13.0	13.6	13.4	9.9	13.1	12.1	12.0	11.7	8.9	11.9
60-64	12.3	13.8	12.5	11.6	12.8	14.0	15.1	7.5	10.5	14.2	13.2	14.5	10.3	11.0	13.5
65-69	12.7	14.5	16.0	11.5	13.2	15.0	15.9	15.8	13.0	15.2	13.8	15.2	15.9	12.3	14.2
70-79	13.3	13.7	16.1	9.3	13.3	15.1	18.0	12.8	11.4	15.7	14.1	16.0	14.3	10.4	14.4
80+	14.6	16.9	10.3	11.2	14.8	15.8	20.0	16.4	12.7	16.6	15.1	18.6	13.3	11.9	15.6
All	11.7	11.9	12.4	8.8	11.7	13.8	15.0	11.7	11.0	14.1	12.6	13.4	12.1	10.0	12.8
ALL															
0-19	9.5	10.1	5.8	8.1	9.7	9.9	14.8	10.6	11.0	12.0	9.7	12.4	8.5	9.6	10.7
20-29	7.6	7.4	7.7	4.4	7.4	11.2	12.3	10.7	7.9	11.5	9.2	9.6	9.4	6.1	9.3
30-39	10.5	9.8	11.5	7.1	10.1	12.8	12.6	12.5	8.4	12.5	11.4	11.0	12.0	7.7	11.1
40-49	11.7	10.6	10.5	7.4	10.9	14.1	13.4	11.1	9.6	13.5	12.6	11.7	10.8	8.5	12.0
50-59	13.2	11.8	12.8	9.5	12.4	16.0	15.0	14.2	11.6	15.3	14.4	13.3	13.5	10.5	13.7
60-64	14.7	13.6	13.6	11.4	14.1	16.8	15.6	15.0	13.1	16.1	15.7	14.7	14.4	12.2	15.1
65-69	14.8	14.8	14.7	12.2	14.7	17.0	16.8	15.7	13.0	16.7	15.9	16.0	15.3	12.6	15.8
70-79	14.7	14.9	15.1	11.7	14.7	17.0	18.0	14.5	12.6	17.1	15.8	16.8	14.7	12.2	16.0
80+	14.8	16.9	15.3	11.5	15.1	16.8	18.9	15.3	12.6	17.3	15.7	18.2	15.3	12.1	16.2
All	13.6	12.3	12.8	10.1	13.0	16.1	15.8	14.1	11.7	15.8	14.8	14.1	13.5	10.9	14.3

Includes all patients who have reached day 91 of ESRD by December 31 of each calendar year.
 Patient age is determined on January 1 of each calendar year.
 * Values for cells with fewer than 10 patients are suppressed.
 "." Zero patients in this cell.

Table E.21

Hospital Days: Hemodialysis Patients, 2000

per patient year, period prevalent patients, by primary diagnosis & age; grouped by gender & race

DIABETES	Male					Female					All				
	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All
0-19	*	*	.	.	*	*	*	*	.	.	*
20-29	16.6	20.1	*	*	17.9	22.8	20.8	15.0	*	21.0	19.4	20.5	14.0	3.8	19.5
30-39	16.8	16.7	20.6	12.3	16.8	19.4	18.8	18.1	12.4	18.8	17.7	17.7	19.4	12.3	17.6
40-49	15.7	15.4	11.1	12.9	15.3	19.7	17.4	11.6	17.8	18.2	17.2	16.3	11.3	14.8	16.5
50-59	15.7	15.1	12.3	11.4	15.1	18.0	17.3	14.2	13.3	17.3	16.7	16.3	13.3	12.2	16.2
60-64	15.7	14.7	12.1	16.3	15.2	17.7	17.0	15.7	14.9	17.2	16.7	16.1	14.0	15.5	16.3
65-69	17.0	16.3	16.6	13.5	16.6	17.7	17.8	18.4	12.5	17.6	17.4	17.3	17.8	13.0	17.2
70-79	17.3	16.5	15.0	14.8	16.9	18.3	18.8	15.6	16.4	18.4	17.8	18.1	15.4	15.8	17.8
80 +	17.0	18.7	16.5	14.9	17.3	18.4	19.4	15.1	14.6	18.6	17.8	19.2	15.6	14.7	18.0
All	16.5	15.8	13.4	13.7	16.1	18.2	18.0	15.5	14.8	17.9	17.4	17.1	14.6	14.3	17.1
HYPERTENSION															
0-19	*	15.3	*	.	13.5	*	9.8	.	*	9.4	*	12.1	*	*	11.0
20-29	4.3	4.9	*	2.4	4.7	8.9	7.1	19.6	*	7.9	6.0	5.6	12.9	2.0	5.7
30-39	8.9	8.0	2.3	8.2	8.1	10.9	10.0	*	7.4	10.2	9.6	8.7	4.2	7.9	8.8
40-49	8.9	8.4	9.4	6.0	8.5	12.7	10.5	8.6	12.2	10.9	10.1	9.1	9.1	8.7	9.3
50-59	11.4	9.6	12.2	7.8	10.0	13.2	12.3	7.2	13.5	12.5	12.0	10.6	10.5	10.1	10.9
60-64	13.3	11.6	7.8	10.5	12.1	15.7	13.2	22.5	10.6	14.0	14.3	12.3	15.5	10.5	12.9
65-69	11.7	12.1	20.4	8.1	11.8	15.4	15.2	14.9	8.3	15.0	13.3	13.7	17.3	8.2	13.4
70-79	13.3	14.3	15.9	12.5	13.6	16.1	16.8	13.3	8.7	16.1	14.5	15.8	14.3	10.6	14.8
80 +	13.8	16.3	16.3	10.7	14.2	14.8	17.3	12.9	13.3	15.6	14.3	16.9	14.0	12.0	14.9
All	12.6	10.5	11.7	9.9	11.4	15.2	14.0	13.6	10.4	14.4	13.7	12.0	12.6	10.2	12.7
GLOMERULONEPHRITIS															
0-19	10.3	6.2	*	*	8.3	9.3	11.0	.	*	9.7	9.8	8.7	*	5.2	9.0
20-29	5.6	6.1	2.1	3.3	5.7	6.5	8.3	5.2	4.2	7.3	6.0	7.1	3.5	3.7	6.3
30-39	5.3	7.0	5.9	7.1	6.2	7.9	9.2	11.0	5.1	8.5	6.2	7.9	8.1	6.4	7.1
40-49	8.0	9.2	6.2	6.0	8.5	9.5	11.3	10.1	5.7	10.0	8.5	9.9	7.4	5.9	9.0
50-59	8.5	9.1	8.5	7.0	8.7	11.6	11.3	16.3	6.3	11.3	9.7	9.9	11.8	6.7	9.7
60-64	10.0	10.4	2.2	6.6	9.9	12.9	11.9	15.3	7.5	12.3	11.1	11.1	10.3	7.0	10.9
65-69	10.8	10.6	7.0	9.9	10.7	12.9	13.7	10.9	5.7	12.6	11.7	12.1	8.9	7.4	11.6
70-79	11.8	11.0	10.4	9.6	11.6	15.2	15.5	10.9	13.5	15.1	13.1	13.4	10.7	11.5	13.0
80 +	14.0	14.0	*	10.4	13.9	14.5	16.8	17.2	7.8	14.5	14.2	15.5	18.3	9.0	14.2
All	9.6	8.7	6.7	7.3	9.1	12.0	11.4	11.8	7.2	11.5	10.5	9.8	9.0	7.3	10.1
OTHER															
0-19	10.1	10.7	*	*	10.1	9.1	20.1	.	*	16.0	9.7	15.0	*	*	12.5
20-29	6.8	7.9	13.0	4.0	7.2	11.3	13.5	6.4	11.7	12.2	8.8	10.7	9.2	8.2	9.6
30-39	7.2	10.4	17.3	2.7	8.7	10.2	13.7	9.7	9.2	11.9	8.5	12.0	13.3	5.8	10.2
40-49	8.9	11.0	9.2	4.6	9.9	12.5	12.2	6.9	11.1	12.2	10.4	11.5	8.5	8.1	10.9
50-59	11.3	10.1	11.7	6.1	10.7	12.5	13.5	7.4	9.0	12.7	11.9	11.7	9.6	7.7	11.6
60-64	11.8	14.8	17.5	16.3	13.0	13.6	15.2	2.6	8.4	13.9	12.7	15.0	10.8	11.8	13.5
65-69	12.9	14.2	19.2	11.4	13.2	14.8	14.9	9.2	15.0	14.8	13.8	14.6	14.2	13.2	14.0
70-79	12.9	14.3	8.0	8.3	13.0	14.7	17.1	11.7	11.6	15.1	13.7	15.8	9.9	10.1	14.0
80 +	14.7	15.5	13.7	8.6	14.6	15.8	20.6	7.5	9.0	16.4	15.1	18.1	10.5	8.8	15.4
All	11.5	11.7	12.1	7.4	11.5	13.6	14.5	8.1	11.2	13.8	12.5	13.0	10.2	9.4	12.5
ALL															
0-19	10.1	9.8	*	*	9.8	9.0	15.8	.	28.1	13.4	9.7	12.8	*	20.9	11.4
20-29	7.1	7.1	5.7	3.5	6.9	10.8	11.5	10.2	7.5	11.0	8.7	9.0	8.2	5.4	8.7
30-39	9.9	9.3	12.7	7.0	9.6	12.2	12.4	13.1	8.3	12.2	10.8	10.6	12.9	7.5	10.6
40-49	11.2	10.3	9.7	7.7	10.6	14.6	12.9	10.5	10.8	13.4	12.5	11.3	10.0	9.2	11.7
50-59	13.1	11.5	11.9	9.1	12.1	15.3	14.8	13.4	11.0	14.8	14.1	13.0	12.7	10.0	13.3
60-64	13.9	13.3	11.6	13.4	13.5	16.2	15.5	15.6	12.4	15.7	15.0	14.5	13.8	12.9	14.7
65-69	14.3	14.1	16.4	11.7	14.2	16.4	16.6	17.5	11.2	16.4	15.4	15.6	17.1	11.4	15.4
70-79	14.4	15.0	13.9	12.5	14.4	16.8	17.8	14.7	13.4	17.0	15.5	16.8	14.4	13.0	15.8
80 +	14.6	16.7	16.2	11.7	14.9	15.9	18.4	13.8	12.7	16.5	15.2	17.7	14.6	12.2	15.7
All	13.3	12.0	12.2	10.4	12.7	15.8	15.6	14.3	11.9	15.6	14.5	13.8	13.3	11.2	14.1

Includes all patients who have reached day 91 of ESRD by December 31 of each calendar year.

Patient age is determined on January 1 of each calendar year.

* Values for cells with fewer than 10 patients are suppressed.

." Zero patients in this cell.

Table E.22

Hospital Days: Hemodialysis Patients, 1998-2000 Combined

per patient year, period prevalent patients, by primary diagnosis & age; grouped by gender & race

DIABETES	Male					Female					All				
	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All
0-19	*	*	.	.	*	*	*	.	.	*	*	27.1	.	.	34.1
20-29	15.1	20.3	*	2.5	16.9	20.8	23.6	10.1	4.6	21.7	17.8	22.3	9.7	3.5	19.5
30-39	16.9	17.7	13.9	8.6	16.9	19.8	20.0	19.0	13.5	19.6	17.9	18.8	16.4	11.1	18.0
40-49	16.4	15.3	12.5	11.0	15.7	19.0	17.5	12.4	15.9	17.9	17.4	16.4	12.4	13.1	16.7
50-59	15.7	15.0	13.4	12.0	15.2	18.2	17.2	14.1	14.2	17.4	16.8	16.2	13.8	13.0	16.3
60-64	16.5	15.5	14.6	13.0	15.9	18.0	17.1	14.6	15.5	17.4	17.3	16.4	14.6	14.3	16.7
65-69	17.2	16.4	15.4	13.5	16.7	18.3	17.8	16.0	14.7	17.8	17.8	17.3	15.8	14.2	17.4
70-79	17.5	16.6	14.6	13.8	17.1	18.4	18.6	15.0	14.9	18.3	18.0	18.0	14.9	14.5	17.8
80+	17.8	18.1	17.2	12.3	17.6	19.5	20.0	16.5	14.8	19.4	18.7	19.5	16.7	13.7	18.7
All	16.8	15.9	14.0	12.7	16.3	18.5	18.0	14.8	14.8	18.0	17.7	17.2	14.4	13.8	17.2
HYPERTENSION															
0-19	7.3	4.9	*	.	5.2	1.8	13.2	.	*	12.1	4.8	8.4	*	*	8.2
20-29	4.6	5.1	5.6	3.2	5.0	7.6	7.6	15.3	3.2	7.8	5.8	5.9	10.9	3.2	5.9
30-39	7.8	8.2	8.0	6.3	8.1	8.7	9.7	18.8	4.7	9.5	8.2	8.7	10.3	5.8	8.5
40-49	8.7	8.6	9.2	4.9	8.6	11.4	10.6	7.2	11.8	10.7	9.5	9.2	8.5	7.8	9.3
50-59	11.1	9.6	12.7	7.7	10.0	13.8	12.3	9.3	12.2	12.6	12.1	10.6	11.3	9.5	10.9
60-64	13.0	11.3	8.5	9.0	11.8	15.3	12.8	16.8	11.4	13.5	13.9	12.0	13.0	9.9	12.6
65-69	12.1	12.6	16.0	8.3	12.3	15.9	14.8	15.4	9.4	15.1	13.7	13.8	15.6	8.9	13.6
70-79	13.5	14.0	14.5	11.2	13.6	15.9	16.8	13.2	8.7	16.1	14.5	15.7	13.7	10.0	14.8
80+	14.0	16.0	16.4	10.8	14.3	16.0	18.1	12.9	10.6	16.5	14.9	17.3	14.0	10.7	15.4
All	12.7	10.5	11.6	9.1	11.4	15.3	14.1	12.8	9.8	14.4	13.8	12.1	12.2	9.5	12.7
GLOMERULONEPHRITIS															
0-19	8.8	7.7	*	11.5	8.3	9.4	9.0	*	1.3	8.6	9.0	8.4	4.5	6.1	8.4
20-29	5.9	5.6	6.0	3.3	5.6	8.0	7.8	9.2	5.6	7.8	6.7	6.5	7.4	4.4	6.5
30-39	5.8	7.3	5.4	5.5	6.5	9.1	9.3	8.0	4.9	9.0	7.0	8.1	6.5	5.3	7.5
40-49	8.1	9.7	6.8	6.0	8.8	9.3	11.2	8.5	5.6	9.9	8.5	10.2	7.3	5.8	9.2
50-59	8.7	9.6	9.5	6.7	9.0	12.0	11.0	14.6	8.4	11.5	10.0	10.2	11.6	7.5	10.0
60-64	11.0	10.1	5.6	8.5	10.5	12.5	11.5	14.5	11.3	12.1	11.6	10.7	10.6	9.6	11.2
65-69	11.9	12.3	11.5	15.6	12.1	12.5	14.2	5.3	5.8	12.5	12.1	13.2	8.3	10.0	12.3
70-79	11.6	11.4	13.4	8.5	11.5	14.9	14.7	8.2	12.1	14.6	12.9	13.1	10.9	10.3	12.8
80+	13.6	15.9	15.7	11.0	13.8	15.1	15.7	11.4	12.1	15.0	14.2	15.8	13.1	11.6	14.3
All	9.8	9.1	8.1	7.3	9.4	12.2	11.2	9.8	8.0	11.6	10.7	9.9	8.8	7.6	10.3
OTHER															
0-19	8.4	9.6	6.3	12.3	8.9	9.8	16.0	4.2	18.3	12.7	9.0	12.6	5.5	16.1	10.5
20-29	7.0	8.3	10.1	4.3	7.5	10.9	13.7	15.5	12.9	12.3	8.7	11.1	12.9	9.1	9.8
30-39	7.8	10.5	20.4	6.9	9.2	11.1	13.1	9.8	8.7	12.0	9.3	11.7	15.2	7.9	10.5
40-49	9.1	11.2	8.8	5.9	10.1	11.9	13.5	6.8	10.4	12.5	10.3	12.2	8.1	8.3	11.1
50-59	11.0	10.3	9.7	7.6	10.6	13.0	13.4	13.4	9.9	13.0	11.9	11.8	11.5	8.8	11.8
60-64	12.3	13.6	13.5	12.1	12.8	13.8	14.8	6.4	10.6	14.0	13.0	14.3	10.5	11.3	13.4
65-69	12.9	14.4	16.0	11.7	13.3	14.7	15.6	13.1	12.9	14.9	13.8	15.1	14.5	12.3	14.1
70-79	13.1	13.6	14.9	9.0	13.1	15.1	17.7	13.1	11.9	15.6	14.0	15.8	13.9	10.7	14.3
80+	14.4	16.9	10.7	11.7	14.7	15.6	20.0	16.4	12.9	16.4	14.9	18.6	13.7	12.3	15.5
All	11.6	11.7	12.5	8.5	11.6	13.7	14.8	11.5	11.2	14.0	12.6	13.2	12.0	10.0	12.7
ALL															
0-19	8.5	8.6	5.4	11.9	8.6	10.0	13.4	4.6	11.5	11.6	9.1	10.8	5.0	11.6	9.9
20-29	7.2	7.0	7.3	3.6	7.0	10.9	11.8	12.4	8.8	11.3	8.8	9.1	9.9	6.1	8.9
30-39	10.1	9.6	11.7	6.4	9.8	12.7	12.4	13.0	7.9	12.4	11.1	10.7	12.3	7.1	10.8
40-49	11.5	10.5	10.4	7.0	10.8	13.9	13.3	10.6	10.3	13.4	12.4	11.5	10.5	8.5	11.8
50-59	13.0	11.5	12.7	9.5	12.1	15.6	14.7	13.7	11.8	15.0	14.1	13.0	13.2	10.5	13.4
60-64	14.4	13.3	13.4	11.3	13.8	16.4	15.4	14.4	13.6	15.7	15.3	14.4	14.0	12.4	14.8
65-69	14.5	14.4	15.2	12.2	14.4	16.7	16.5	15.2	12.3	16.5	15.7	15.7	15.2	12.3	15.5
70-79	14.5	14.8	14.5	11.6	14.5	16.8	17.7	14.2	12.5	16.9	15.6	16.6	14.3	12.1	15.8
80+	14.7	16.7	15.4	11.4	15.0	16.7	18.9	15.2	12.5	17.2	15.6	18.1	15.2	12.0	16.1
All	13.5	12.1	12.7	10.0	12.8	16.0	15.7	13.8	11.9	15.6	14.6	13.9	13.3	10.9	14.2

Includes all patients who have reached day 91 of ESRD by December 31 of each calendar year.
 Patient age is determined on January 1 of each calendar year.
 * Values for cells with fewer than 10 patients are suppressed.
 ." Zero values in this cell.

Table E.23

Hospital Days: CAPD/CCPD Patients, 2000

per patient year, period prevalent patients, by primary diagnosis & age; grouped by gender & race

DIABETES	Male					Female					All				
	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All
0-19
20-29	12.3	21.2	*	*	14.3	16.4	23.2	*	*	18.6	15.1	22.6	*	*	17.2
30-39	18.0	20.7	*	*	18.1	17.8	22.4	*	*	18.9	17.9	21.7	10.0	*	18.5
40-49	18.1	19.3	8.8	21.0	18.1	24.1	27.0	12.8	5.6	23.7	20.6	23.3	11.3	12.1	20.7
50-59	17.7	19.4	12.7	8.3	17.5	22.1	23.2	17.6	32.9	22.5	19.6	21.8	15.4	18.6	19.9
60-64	18.9	19.4	23.9	13.6	19.0	24.7	22.5	22.0	2.8	23.0	21.6	21.3	22.9	7.1	21.0
65-69	20.0	22.1	8.3	7.4	19.7	21.2	22.3	16.8	14.2	20.9	20.6	22.2	13.5	12.3	20.3
70-79	19.3	17.3	27.0	10.7	18.8	20.9	30.5	30.7	21.5	23.4	20.0	26.1	28.8	15.6	21.1
80 +	14.3	*	.	*	14.4	23.4	22.9	*	*	24.1	18.1	21.9	*	29.6	19.1
All	18.5	19.6	13.9	10.9	18.3	21.8	24.6	18.2	16.9	22.3	20.0	22.7	16.3	14.3	20.3
HYPERTENSION															
0-19	*	*	.	*	*	*	*	.	*	*	*	*	.	*	9.1
20-29	3.1	5.8	*	*	4.4	6.6	12.0	*	*	9.1	4.8	9.1	*	1.3	6.8
30-39	10.3	15.6	*	*	14.0	9.4	10.5	*	*	10.0	9.9	13.2	*	11.5	12.1
40-49	9.5	8.0	*	2.1	8.6	7.8	10.3	*	3.1	9.5	8.9	9.1	22.4	2.7	9.0
50-59	10.9	12.3	*	11.8	11.5	15.8	16.8	*	8.7	16.0	12.7	14.6	*	10.1	13.6
60-64	12.4	26.0	*	*	16.8	15.5	17.0	*	*	16.2	13.7	20.3	*	10.2	16.5
65-69	14.6	11.2	*	*	13.8	13.3	18.7	*	2.7	14.3	14.0	15.5	*	5.7	14.0
70-79	13.5	14.9	*	11.9	13.6	18.3	19.6	*	23.0	18.7	15.4	17.2	*	16.4	15.7
80 +	14.0	31.7	.	10.6	14.8	17.1	19.1	.	*	17.9	15.3	23.9	.	18.2	16.1
All	12.6	12.4	18.1	9.8	12.4	15.1	14.6	11.6	10.6	14.6	13.6	13.5	14.8	10.2	13.4
GLOMERULONEPHRITIS															
0-19	6.2	5.2	*	*	5.8	9.8	11.8	*	*	10.2	8.4	9.0	*	*	8.4
20-29	9.3	9.0	*	1.3	8.5	8.9	13.4	*	1.6	10.2	9.1	11.6	4.7	1.4	9.5
30-39	4.7	7.6	*	5.7	5.6	6.0	10.5	6.3	1.8	7.8	5.4	9.6	5.4	4.4	6.9
40-49	9.4	10.8	*	0.7	9.3	10.4	9.3	*	3.2	9.0	9.9	10.0	3.7	2.5	9.2
50-59	8.7	16.2	*	3.4	10.1	12.6	14.2	*	4.8	12.6	10.5	15.2	18.2	4.2	11.4
60-64	12.2	17.8	*	*	12.5	10.5	13.6	*	*	11.6	11.4	14.7	*	*	12.0
65-69	10.7	21.4	*	*	12.3	10.9	24.9	.	*	15.4	10.8	23.8	*	*	13.7
70-79	12.8	11.2	.	*	12.7	17.0	16.2	*	*	16.8	14.3	14.3	*	11.4	14.3
80 +	12.4	*	.	*	12.3	19.2	*	*	*	17.7	14.8	*	*	*	14.3
All	9.9	11.4	2.5	5.6	9.9	11.2	12.3	9.2	5.4	11.1	10.5	12.0	6.9	5.5	10.5
OTHER															
0-19	7.4	13.4	.	*	9.0	10.1	16.3	*	*	12.1	8.8	14.9	*	9.2	10.6
20-29	11.4	12.6	*	*	11.4	11.9	10.2	*	6.7	10.7	11.7	11.1	*	6.1	11.0
30-39	11.8	11.1	*	8.5	11.5	9.4	16.3	*	12.5	12.5	10.3	14.4	20.3	10.9	12.1
40-49	9.8	10.7	*	7.7	10.0	14.9	13.8	4.3	7.3	13.8	12.8	12.7	4.5	7.4	12.3
50-59	10.5	15.6	*	4.6	11.4	13.6	11.5	*	10.5	12.8	12.3	13.0	*	8.2	12.3
60-64	11.5	15.0	*	*	12.0	15.0	21.3	*	*	15.9	13.6	18.7	*	*	14.3
65-69	11.4	16.1	.	*	11.9	14.6	16.4	*	*	14.8	13.0	16.3	*	6.3	13.4
70-79	15.1	21.5	*	11.0	15.3	12.8	36.1	*	10.9	15.3	14.2	29.4	*	11.0	15.3
80 +	16.6	*	*	*	15.8	24.0	*	.	*	24.2	19.3	*	*	*	18.9
All	12.1	13.1	9.9	7.4	12.2	13.4	14.9	11.9	9.2	13.6	12.8	14.2	11.2	8.5	13.0
ALL															
0-19	7.2	10.7	*	5.1	8.1	9.9	14.2	*	*	11.5	8.6	12.6	*	10.2	9.9
20-29	9.6	10.0	3.2	2.0	9.3	11.1	12.6	4.8	5.0	11.2	10.4	11.6	4.3	3.8	10.4
30-39	12.2	13.5	11.2	8.1	12.4	11.0	14.1	11.1	8.1	12.2	11.6	13.8	11.1	8.1	12.3
40-49	13.1	10.9	11.3	6.2	12.0	16.2	13.6	9.4	4.6	14.2	14.6	12.3	10.0	5.2	13.1
50-59	13.5	15.3	10.1	7.2	13.7	16.8	17.7	18.0	13.1	17.0	15.1	16.6	14.1	10.4	15.4
60-64	15.5	20.8	19.6	11.2	16.6	19.0	19.4	20.8	6.1	18.7	17.2	19.9	20.1	8.6	17.7
65-69	15.5	17.1	8.1	12.5	15.5	16.4	20.9	20.2	11.8	17.4	15.9	19.4	14.6	12.0	16.5
70-79	15.5	16.3	25.0	11.3	15.5	17.9	26.7	25.5	18.2	19.7	16.5	22.4	25.3	14.4	17.3
80 +	14.4	23.8	*	8.0	14.6	20.0	20.7	*	25.2	20.3	16.6	21.8	*	18.1	17.0
All	14.1	14.0	12.3	8.4	13.8	16.2	17.0	14.5	10.5	16.1	15.1	15.7	13.6	9.5	15.0

Includes all patients who have reached day 91 of ESRD by December 31 of each calendar year.

Patient age is determined on January 1 of each calendar year.

* Values for cells with fewer than 10 patients are suppressed.

." Zero values in this cell.

Table E.24
Hospital Days: CAPD/CCPD Patients, 1998-2000 Combined
per patient year, period prevalent patients, by primary diagnosis & age; grouped by gender & race

DIABETES	Male					Female					All				
	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All
0-19	*	*	.	.	*	*
20-29	12.6	16.1	*	*	14.4	17.1	26.1	*	*	19.5	15.4	22.1	20.5	*	17.6
30-39	17.3	15.7	4.7	*	16.8	19.5	22.0	28.6	32.0	20.5	18.3	19.4	16.4	26.5	18.5
40-49	16.0	19.3	14.3	16.8	16.6	19.8	25.5	17.8	7.2	21.0	17.6	22.7	16.3	11.0	18.6
50-59	18.5	21.7	13.7	10.4	18.7	24.1	23.3	18.8	20.1	23.4	20.9	22.7	16.6	14.5	21.0
60-64	19.9	19.4	18.8	15.2	19.6	24.1	23.0	18.2	10.9	23.0	22.0	21.5	18.5	12.6	21.4
65-69	20.4	24.7	7.0	10.3	20.5	22.7	22.6	20.4	21.9	22.6	21.5	23.4	14.6	17.1	21.5
70-79	20.9	19.4	22.0	11.8	20.5	22.8	27.7	23.2	15.1	23.6	21.7	24.8	22.7	13.7	22.0
80+	19.1	35.2	.	17.5	20.2	23.0	24.3	*	19.1	23.0	21.1	26.9	*	18.7	21.7
All	18.8	20.5	14.2	12.3	18.9	22.3	24.1	19.8	17.0	22.5	20.4	22.7	17.5	14.9	20.7
HYPERTENSION															
0-19	*	*	.	*	7.6	*	*	.	*	5.1	5.4	3.8	.	*	6.1
20-29	5.6	8.2	*	2.1	6.9	4.8	9.5	*	1.9	7.2	5.2	8.8	10.0	2.0	7.1
30-39	9.4	11.1	*	12.8	10.7	11.4	9.9	3.1	5.7	9.9	10.3	10.6	5.7	8.5	10.3
40-49	8.4	10.9	16.1	12.6	10.3	10.4	9.9	13.5	15.0	10.3	9.2	10.4	14.7	13.7	10.3
50-59	11.4	13.5	13.2	8.6	12.4	15.0	16.3	*	8.6	15.4	12.8	14.9	11.4	8.6	13.8
60-64	14.0	19.2	*	6.0	15.6	17.1	14.5	*	4.7	15.5	15.4	16.3	35.7	5.3	15.5
65-69	13.5	18.5	10.8	12.8	14.5	14.8	19.7	*	6.5	16.0	14.1	19.2	23.0	8.8	15.2
70-79	14.8	18.1	*	10.1	15.0	18.2	18.4	17.2	15.6	18.1	16.2	18.2	14.7	12.2	16.3
80+	14.1	26.4	*	10.6	14.6	17.9	19.8	*	12.8	17.8	15.6	22.3	*	11.7	16.0
All	13.0	13.4	15.4	9.9	13.1	15.8	13.9	15.1	10.0	14.7	14.2	13.6	15.2	10.0	13.8
GLOMERULONEPHRITIS															
0-19	7.1	5.3	*	4.0	6.3	9.1	11.8	*	*	9.8	8.3	9.1	10.6	3.7	8.4
20-29	8.6	9.3	7.0	8.3	8.8	9.4	12.7	4.0	2.8	10.2	9.1	11.3	5.2	5.5	9.6
30-39	6.6	10.9	*	6.4	7.9	8.9	9.7	5.2	4.0	8.8	7.8	10.2	5.5	5.3	8.4
40-49	9.1	9.9	5.0	2.7	8.9	9.2	10.4	10.2	3.9	9.1	9.2	10.2	7.5	3.5	9.0
50-59	10.2	13.7	4.1	7.0	10.8	13.5	13.1	*	3.6	12.7	11.8	13.4	11.4	5.0	11.7
60-64	12.3	15.0	*	15.4	12.6	14.1	14.9	*	*	14.7	13.1	14.9	24.6	12.7	13.6
65-69	12.8	21.1	*	17.4	13.7	12.4	16.4	*	24.3	13.7	12.6	17.9	*	20.6	13.7
70-79	13.5	12.8	*	7.8	13.4	16.6	14.4	*	9.8	16.0	14.7	13.7	15.2	8.6	14.4
80+	13.7	22.2	*	*	14.4	16.0	*	*	*	15.2	14.6	17.4	*	*	14.7
All	10.7	11.3	7.2	7.3	10.6	11.8	11.8	9.1	5.1	11.3	11.2	11.6	8.4	6.1	11.0
OTHER															
0-19	12.1	15.4	.	6.7	12.9	10.6	20.6	*	11.7	13.9	11.4	17.9	*	9.0	13.4
20-29	9.5	12.8	*	2.7	10.4	13.4	14.7	*	7.5	13.3	11.8	13.9	1.5	6.3	12.1
30-39	11.5	12.0	10.2	15.2	11.9	10.1	16.0	11.3	11.8	12.5	10.7	14.6	10.9	13.1	12.3
40-49	9.4	11.0	9.9	11.3	10.1	13.0	15.1	10.6	8.6	13.5	11.5	13.5	10.3	9.5	12.2
50-59	11.0	14.1	12.3	9.7	11.7	13.2	14.2	13.6	9.9	13.3	12.3	14.2	12.8	9.8	12.7
60-64	11.8	18.4	*	*	12.7	14.7	18.5	*	6.9	15.2	13.6	18.5	9.2	6.0	14.2
65-69	10.7	14.7	.	10.0	11.2	15.9	20.2	27.6	13.3	16.5	13.4	17.6	27.6	12.0	14.0
70-79	14.3	14.5	30.6	9.9	14.3	15.8	27.2	10.6	6.3	16.5	14.9	21.4	17.5	8.1	15.2
80+	16.3	17.4	*	*	15.7	18.8	17.8	.	*	18.5	17.3	17.7	*	1.8	16.8
All	11.9	13.1	11.5	10.0	12.1	13.7	16.2	12.9	9.5	14.2	12.8	15.0	12.4	9.7	13.2
ALL															
0-19	10.8	12.3	*	5.6	11.0	9.9	16.7	19.6	10.1	12.3	10.4	14.6	18.2	7.7	11.7
20-29	9.2	10.6	10.4	6.1	9.6	11.8	13.9	6.0	5.4	12.1	10.7	12.5	7.3	5.7	11.0
30-39	12.4	12.0	7.7	10.7	12.1	12.7	13.6	10.4	9.8	12.9	12.6	12.9	9.6	10.2	12.5
40-49	12.0	12.1	11.6	9.0	11.9	14.1	14.2	14.0	7.2	13.7	13.0	13.2	13.0	7.9	12.8
50-59	14.2	16.1	12.6	9.0	14.6	17.6	17.9	17.9	10.1	17.4	15.8	17.1	15.3	9.6	16.0
60-64	16.2	18.8	16.9	11.6	16.6	19.3	18.6	22.9	8.5	18.7	17.7	18.6	20.1	9.8	17.7
65-69	15.5	20.8	7.9	12.0	16.1	17.9	20.8	23.8	17.0	18.6	16.6	20.8	17.1	14.9	17.4
70-79	16.3	17.6	22.3	10.2	16.3	19.0	23.5	18.3	12.8	19.6	17.4	21.1	19.9	11.4	17.7
80+	15.2	26.5	*	10.9	15.6	18.9	20.7	*	13.8	18.8	16.7	22.8	18.5	12.5	17.0
All	14.4	14.7	12.8	9.8	14.3	16.6	16.9	16.0	10.3	16.4	15.4	15.9	14.6	10.1	15.3

Includes all patients who have reached day 91 of ESRD by December 31 of each calendar year.
 Patient age is determined on January 1 of each calendar year.
 * Values for cells with fewer than 10 patients are suppressed.
 "." Zero values in this cell.

Table E.25

Hospital Days: Transplant Patients, 2000

per patient year, period prevalent patients, by primary diagnosis & age; grouped by gender & race

DIABETES	Male					Female					All				
	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All
0-19	*	.	.	.	*	*	.	.	.	*
20-29	8.0	6.3	.	*	7.6	10.1	5.9	.	*	8.7	9.0	6.1	.	*	8.2
30-39	6.7	8.1	*	*	7.1	8.9	9.6	*	3.4	9.1	7.6	8.8	25.5	2.3	7.9
40-49	6.8	9.3	3.4	1.0	7.0	6.4	11.1	*	6.8	7.3	6.7	10.0	5.0	3.6	7.1
50-59	7.3	12.0	6.4	5.4	8.3	7.8	8.7	7.3	7.5	8.0	7.5	10.6	6.8	6.2	8.2
60-64	10.4	8.7	8.7	7.4	9.8	9.6	7.8	8.1	3.3	8.5	10.2	8.3	8.5	5.6	9.3
65-69	8.0	7.9	*	6.3	7.9	9.9	9.0	*	10.4	9.5	8.7	8.3	6.0	8.1	8.5
70-79	11.1	10.9	*	*	10.7	15.4	10.1	*	*	12.4	12.2	10.5	*	*	11.3
80+	*	.	.	.	*	*	.	.	.	*
All	7.5	9.7	8.6	4.5	7.9	8.2	9.0	8.5	6.3	8.4	7.8	9.4	8.5	5.3	8.1
HYPERTENSION															
0-19	*	*	.	.	*	*	*	*	*	*	*	*	*	*	*
20-29	0.7	2.3	*	5.5	2.0	3.6	7.1	*	*	5.5	1.8	3.7	*	5.3	3.1
30-39	2.5	4.1	*	2.0	3.4	3.4	4.3	*	1.7	3.8	2.9	4.2	*	1.9	3.5
40-49	4.1	5.2	1.2	3.1	4.7	3.2	5.1	*	0.4	4.0	3.8	5.2	2.0	2.0	4.5
50-59	3.5	5.3	*	1.5	4.4	5.1	7.1	*	3.1	5.9	4.0	5.9	3.2	2.4	5.0
60-64	6.4	7.9	*	5.7	6.9	5.4	4.0	.	*	4.7	6.0	6.3	*	4.7	6.0
65-69	3.5	12.4	.	5.4	6.0	4.7	5.4	.	*	4.9	3.9	9.3	.	5.0	5.6
70-79	4.3	9.4	.	*	5.0	8.5	2.0	.	*	7.0	5.6	6.0	.	*	5.7
80+	*	*	.	.	*	*	.	.	.	*	*	*	.	.	*
All	3.8	5.4	2.4	3.2	4.5	4.6	5.5	5.2	2.6	4.9	4.1	5.4	3.3	3.0	4.7
GLOMERULONEPHRITIS															
0-19	5.9	9.4	*	*	6.9	4.9	8.4	*	*	5.7	5.4	9.1	*	2.2	6.3
20-29	2.3	4.9	*	1.2	3.0	5.6	5.6	*	2.4	5.3	3.6	5.2	.	1.7	3.9
30-39	2.4	5.0	4.3	0.9	3.1	2.8	7.2	*	3.0	4.0	2.6	5.8	2.6	1.9	3.4
40-49	3.4	5.1	1.7	2.3	3.6	3.7	4.8	2.5	1.2	3.6	3.5	5.0	2.1	1.7	3.6
50-59	4.6	4.8	*	4.3	4.6	4.5	5.1	*	1.3	4.3	4.6	4.9	1.6	2.9	4.5
60-64	3.4	5.1	*	*	3.6	7.5	5.3	*	*	6.6	4.7	5.2	*	0.8	4.6
65-69	4.5	14.3	*	*	5.5	6.4	4.8	*	*	6.5	5.3	10.4	*	*	5.9
70-79	4.6	*	*	*	5.2	5.1	*	.	*	5.0	4.7	11.9	*	*	5.1
80+	*	.	.	.	*	*	.	.	.	*	*	.	.	.	*
All	3.5	5.5	2.3	2.0	3.9	4.5	5.9	2.2	2.2	4.6	3.8	5.7	2.3	2.1	4.1
OTHER															
0-19	3.6	5.3	*	0.4	4.0	4.5	12.2	*	7.2	6.0	4.0	7.7	*	4.1	4.8
20-29	2.0	5.6	*	1.6	2.6	5.4	4.2	*	1.9	5.0	3.6	4.8	*	1.8	3.7
30-39	2.9	2.9	*	0.1	2.8	4.6	5.8	*	1.2	4.8	3.8	4.6	*	0.8	3.8
40-49	3.8	2.7	*	0.8	3.6	3.4	6.1	*	0.2	3.8	3.6	4.6	4.2	0.4	3.7
50-59	4.0	8.1	*	12.1	5.0	4.0	4.7	3.2	5.0	4.1	4.0	6.5	4.3	8.1	4.6
60-64	5.3	8.1	*	*	5.9	6.0	3.7	*	*	5.5	5.6	6.2	*	6.5	5.7
65-69	6.1	4.2	*	*	6.1	4.5	8.9	.	*	5.0	5.4	6.5	*	3.7	5.6
70-79	6.2	2.3	.	.	6.0	7.2	*	.	*	6.5	6.5	2.4	.	*	6.1
80+	*	*	.	.	*	*	.	.	.	*	*	*	.	.	*
All	3.8	5.1	7.0	4.3	4.1	4.5	5.9	2.7	2.3	4.6	4.1	5.5	4.7	3.1	4.4
ALL															
0-19	4.1	6.4	*	1.1	4.6	4.6	10.6	*	5.4	5.9	4.3	7.9	6.3	3.3	5.1
20-29	2.6	4.4	0.7	2.0	3.1	6.0	5.3	2.8	2.2	5.6	4.1	4.8	1.8	2.1	4.2
30-39	4.0	4.8	9.9	1.0	4.2	5.5	6.6	7.1	2.3	5.7	4.6	5.6	8.8	1.7	4.8
40-49	4.8	5.5	3.2	2.1	4.8	4.4	6.4	3.7	1.3	4.7	4.6	5.8	3.4	1.6	4.8
50-59	5.2	7.5	5.5	5.6	5.9	5.2	6.8	5.4	3.7	5.6	5.2	7.2	5.5	4.6	5.7
60-64	6.8	7.9	7.9	5.9	7.0	7.1	5.7	6.6	2.2	6.5	6.9	7.0	7.5	4.4	6.8
65-69	5.7	9.6	12.9	4.8	6.5	6.3	7.2	*	9.5	6.6	6.0	8.6	8.3	6.7	6.5
70-79	6.2	9.5	*	*	6.5	8.3	5.3	*	*	7.6	6.8	7.5	*	3.4	6.8
80+	9.3	*	.	.	8.6	*	.	.	.	*	7.8	*	.	.	7.5
All	4.8	6.2	6.0	3.2	5.1	5.4	6.5	5.2	2.9	5.6	5.1	6.4	5.7	3.0	5.3

Includes all patients who have reached day 91 of ESRD by December 31 of each calendar year.

Patient age is determined on January 1 of each calendar year.

First three years after transplant.

* Values for cells with fewer than 10 patients are suppressed.

." Zero patients in this cell.

Table E.26
Hospital Days: Transplant Patients, 1998-2000 Combined
per patient year, period prevalent patients, by primary diagnosis & age; grouped by gender & race

DIABETES	Male					Female					All				
	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All
0-19	*	*	.	.	*	*	.	.	.	*	*	.	.	.	*
20-29	8.1	9.1	*	*	8.3	9.8	7.0	*	*	8.9	8.9	7.9	*	*	8.6
30-39	6.9	8.6	12.8	1.0	7.1	8.0	9.1	15.9	5.4	8.2	7.3	8.8	14.2	3.5	7.6
40-49	7.0	10.5	7.3	2.1	7.5	8.1	11.3	5.2	7.1	8.5	7.4	10.8	6.4	4.4	7.9
50-59	7.8	10.0	7.4	5.7	8.3	8.1	9.1	9.6	8.8	8.5	7.9	9.6	8.4	6.8	8.4
60-64	8.6	9.1	6.0	3.9	8.5	9.9	11.2	5.0	3.7	9.8	9.1	10.1	5.6	3.8	9.0
65-69	6.8	9.4	15.3	5.0	7.5	9.8	10.0	*	8.3	9.7	7.8	9.7	12.1	6.5	8.3
70-79	9.7	9.0	*	*	9.2	9.1	9.9	*	*	9.0	9.6	9.4	*	2.3	9.2
80+	*	.	.	.	*	*	.	.	.	*
All	7.4	9.7	8.1	4.0	7.8	8.4	9.7	8.3	6.6	8.7	7.8	9.7	8.2	5.1	8.1
HYPERTENSION															
0-19	2.8	0.3	.	.	1.6	3.8	*	*	*	6.8	3.3	2.3	*	*	4.2
20-29	2.0	3.8	*	4.2	3.2	3.2	5.3	*	*	4.4	2.4	4.3	3.7	3.9	3.6
30-39	3.4	3.9	11.5	2.9	3.8	4.4	4.2	*	2.4	4.2	3.7	4.0	8.3	2.7	3.9
40-49	4.5	5.1	4.4	2.3	4.7	3.6	5.2	4.6	1.3	4.3	4.2	5.1	4.5	1.8	4.6
50-59	3.8	5.1	7.1	3.3	4.5	4.2	5.8	7.6	2.6	4.9	3.9	5.3	7.3	3.0	4.6
60-64	5.4	7.8	*	3.5	6.2	6.1	6.6	*	2.7	6.1	5.6	7.3	*	3.3	6.2
65-69	5.2	12.9	*	5.4	7.3	5.3	8.0	.	4.9	6.3	5.2	10.7	*	5.2	6.9
70-79	6.9	12.4	.	10.3	8.0	9.1	6.7	.	*	8.4	7.5	9.9	.	10.1	8.1
80+	*	*	.	.	4.4	*	.	.	.	*	5.1	*	.	.	4.2
All	4.4	5.4	6.2	3.5	4.9	4.7	5.6	6.5	2.4	5.0	4.5	5.4	6.3	3.1	4.9
GLOMERULONEPHRITIS															
0-19	4.1	6.7	*	2.7	5.0	4.7	10.1	*	2.4	5.9	4.4	8.0	3.9	2.6	5.4
20-29	2.0	4.0	4.7	2.5	2.7	5.1	5.3	2.0	1.7	4.9	3.2	4.5	3.5	2.2	3.5
30-39	2.3	3.9	2.8	1.5	2.7	3.0	5.1	2.3	1.7	3.4	2.6	4.4	2.6	1.6	3.0
40-49	3.1	5.1	2.8	1.9	3.5	3.3	3.8	5.2	1.8	3.3	3.2	4.6	3.8	1.8	3.4
50-59	4.1	4.8	3.7	2.4	4.2	4.1	6.4	2.5	1.8	4.3	4.1	5.4	3.2	2.1	4.2
60-64	4.4	6.8	3.1	4.0	4.7	5.2	6.2	*	7.9	5.6	4.7	6.6	3.4	5.9	5.0
65-69	5.2	7.3	*	0.7	5.3	5.6	6.6	*	*	6.0	5.4	7.0	*	6.5	5.6
70-79	7.1	9.7	*	*	7.1	5.3	1.5	.	*	4.9	6.6	6.4	*	*	6.5
80+	*	.	.	.	*	*	.	.	.	*	1.6	.	.	.	1.6
All	3.4	4.8	3.1	2.1	3.6	4.1	5.4	3.4	2.3	4.2	3.6	5.0	3.2	2.2	3.8
OTHER															
0-19	3.7	7.0	2.8	2.3	4.4	4.6	10.2	12.6	7.1	5.7	4.1	8.1	7.8	4.3	4.9
20-29	3.0	4.5	1.3	3.1	3.3	5.3	6.5	5.0	2.5	5.4	4.1	5.5	3.2	2.8	4.3
30-39	3.3	3.8	7.8	0.7	3.3	4.5	6.3	5.2	3.0	4.9	3.9	5.2	6.3	2.1	4.1
40-49	3.7	5.8	4.1	2.6	4.0	3.5	6.3	0.9	1.9	4.0	3.6	6.1	2.3	2.2	4.0
50-59	3.8	7.3	4.8	8.4	4.6	4.3	5.0	2.1	3.8	4.4	4.1	6.2	3.0	5.7	4.5
60-64	4.2	6.5	4.6	4.4	4.6	5.3	9.9	3.2	3.3	5.9	4.7	7.9	3.9	3.9	5.2
65-69	7.0	7.0	*	3.8	7.1	6.0	9.4	*	1.1	6.4	6.5	8.0	35.2	2.1	6.8
70-79	7.8	10.7	.	*	8.0	9.8	17.5	.	*	10.6	8.5	13.9	.	11.4	9.0
80+	5.6	*	.	.	5.1	*	.	.	.	*	4.8	*	.	.	4.5
All	4.0	5.9	6.0	3.6	4.3	4.6	6.8	5.2	3.2	5.0	4.3	6.3	5.5	3.3	4.6
ALL															
0-19	3.8	6.7	2.9	2.4	4.5	4.6	10.1	11.1	5.4	5.8	4.1	7.9	7.9	3.7	5.0
20-29	3.1	4.4	2.9	3.0	3.5	5.8	5.9	3.8	2.2	5.6	4.2	5.1	3.4	2.6	4.4
30-39	4.2	4.6	7.7	1.6	4.3	5.3	6.1	7.0	2.6	5.4	4.7	5.3	7.4	2.1	4.8
40-49	4.7	6.1	4.9	2.2	5.0	5.0	6.2	4.0	2.2	5.1	4.8	6.1	4.5	2.2	5.0
50-59	5.1	6.8	6.7	4.6	5.6	5.2	6.8	7.2	3.6	5.6	5.2	6.8	6.9	4.1	5.6
60-64	5.8	7.9	5.4	3.9	6.2	6.6	9.0	4.4	4.7	7.1	6.1	8.4	5.0	4.2	6.6
65-69	6.1	9.9	15.2	4.2	6.9	6.7	8.7	13.5	6.3	7.1	6.3	9.4	14.7	5.1	7.0
70-79	7.7	10.8	*	6.6	8.0	8.6	8.9	*	8.1	8.7	8.0	10.0	*	7.1	8.2
80+	7.4	*	.	.	6.3	2.4	.	.	.	2.4	6.2	*	.	.	5.5
All	4.8	6.2	6.3	3.1	5.1	5.5	6.9	6.2	3.1	5.7	5.1	6.5	6.2	3.1	5.4

Includes all patients who have reached day 91 of ESRD by December 31 of each calendar year.
 Patient age is determined on January 1 of each calendar year.
 First three years after transplant.
 * Values for cells with fewer than 10 patients are suppressed.
 "." Zero values in this cell.

Table E.27

Total Hospital Discharges: by General Diagnostic Related Group*period prevalent patients, 1998-2000 combined, by primary diagnosis & age; grouped by gender & race*

ALL	1998			1999			2000		
	Medical	Procedure	All	Medical	Procedure	All	Medical	Procedure	All
Nervous system	22,092	2,857	24,949	23,041	2,896	25,937	23,984	3,036	27,020
Eye	289	456	745	295	380	675	391	334	725
Ear, nose, & throat	1,731	268	1,999	2,089	226	2,315	2,044	230	2,274
Respiratory system	34,725	1,672	36,397	38,251	1,825	40,076	38,258	2,248	40,506
Circulatory system	99,793	79,862	179,655	107,593	81,225	188,818	114,517	82,125	196,642
Gastrointestinal system	31,529	7,952	39,481	32,211	7,823	40,034	34,134	7,793	41,927
Hepatic system	6,756	2,929	9,685	7,008	3,026	10,034	7,284	3,168	10,452
Muscular/skeletal system	8,998	10,541	19,539	10,033	11,216	21,249	10,669	11,992	22,661
Skin/breast	6,233	3,095	9,328	6,961	3,228	10,189	7,789	3,345	11,134
Endocrine system	18,356	4,025	22,381	19,676	4,358	24,034	21,281	4,453	25,734
Renal system	49,739	28,505	78,244	52,150	28,228	80,378	55,557	28,199	83,756
Male reproduction system	352	671	1,023	348	701	1,049	411	751	1,162
Female reproduction system	392	848	1,240	416	779	1,195	496	896	1,392
Pregnancy	158	81	239	205	85	290	169	92	261
Hematologic system	3,964	253	4,217	4,085	231	4,316	4,488	237	4,725
Myeloproliferative system	1,374	323	1,697	1,392	335	1,727	1,422	368	1,790
Infection	22,118	5,705	27,823	22,088	5,226	27,314	22,039	5,273	27,312
Psychological disorders	5,161	280	5,441	5,468	264	5,732	5,446	226	5,672
Injury/poisoning	6,683	4,640	11,323	7,099	4,582	11,681	7,431	4,511	11,942
Burns	57	66	123	*	*	*	*	*	*
Other factors	11,195	969	12,164	13,503	1,109	14,612	14,504	1,188	15,692
Unclassified	*	3,675	3,675	*	4,750	4,750	*	4,991	4,991
HIV	1,712	176	1,888	1,929	200	2,129	2,107	211	2,318
All	333,407	159,849	493,256	355,841	162,695	518,536	374,421	165,671	540,092
DIALYSIS									
Nervous system	19,711	2,427	22,138	20,541	2,527	23,068	21,280	2,642	23,922
Eye	231	392	623	233	320	553	307	295	602
Ear, nose, & throat	1,222	188	1,410	1,442	144	1,586	1,535	153	1,688
Respiratory system	30,851	1,358	32,209	33,595	1,489	35,084	33,621	1,902	35,523
Circulatory system	92,702	76,053	168,755	100,094	77,333	177,427	106,286	78,003	184,289
Gastrointestinal system	27,743	6,815	34,558	28,060	6,716	34,776	29,565	6,633	36,198
Hepatic system	5,431	2,303	7,734	5,624	2,386	8,010	5,805	2,432	8,237
Muscular/skeletal system	7,742	8,457	16,199	8,575	9,149	17,724	9,267	9,813	19,080
Skin/breast	4,937	2,605	7,542	5,597	2,740	8,337	6,329	2,839	9,168
Endocrine system	14,687	3,474	18,161	15,724	3,765	19,489	17,120	3,794	20,914
Renal system	39,036	17,636	56,672	41,166	17,304	58,470	43,691	17,095	60,786
Male reproduction system	268	529	797	259	530	789	306	551	857
Female reproduction system	291	599	890	326	532	858	391	609	1,000
Pregnancy	64	28	92	89	39	128	90	40	130
Hematologic system	3,256	137	3,393	3,343	140	3,483	3,590	129	3,719
Myeloproliferative system	1,133	247	1,380	1,184	233	1,417	1,175	268	1,443
Infection	18,694	5,019	23,713	18,600	4,604	23,204	18,619	4,602	23,221
Psychological disorders	4,517	271	4,788	4,791	258	5,049	4,664	218	4,882
Injury/poisoning	6,100	4,177	10,277	6,410	4,175	10,585	6,637	3,999	10,636
Burns	47	52	99	*	*	*	*	*	*
Other factors	9,908	909	10,817	12,021	1,027	13,048	12,971	1,092	14,063
Unclassified	*	3,189	3,189	*	4,057	4,057	*	4,288	4,288
HIV	1,666	174	1,840	1,850	198	2,048	2,054	208	2,262
All	290,237	137,039	427,276	309,524	139,668	449,192	325,303	141,608	466,911

One DRG per discharge.

*Values for cells with fewer than 10 discharges are excluded.

Table E.27 (continued)

Total Hospital Discharges: by General Diagnostic Related Group

period prevalent patients, 1998-2000 combined, by primary diagnosis & age; grouped by gender & race

HEMODIALYSIS	1998			1999			2000		
	Medical	Procedure	All	Medical	Procedure	All	Medical	Procedure	All
Nervous system	16,560	2,071	18,631	17,664	2,237	19,901	18,800	2,335	21,135
Eye	200	352	552	202	276	478	268	273	541
Ear, nose, & throat	1,085	161	1,246	1,282	130	1,412	1,393	145	1,538
Respiratory system	27,471	1,194	28,665	30,517	1,333	31,850	30,922	1,730	32,652
Circulatory system	81,478	68,775	150,253	90,151	71,301	161,452	97,471	73,015	170,486
Gastrointestinal system	21,311	5,138	26,449	22,572	5,311	27,883	24,350	5,388	29,738
Hepatic system	4,559	1,949	6,508	4,940	2,065	7,005	5,101	2,132	7,233
Muscular/skeletal system	6,927	7,501	14,428	7,800	8,306	16,106	8,514	9,023	17,537
Skin/breast	4,351	2,296	6,647	5,020	2,455	7,475	5,712	2,543	8,255
Endocrine system	11,895	3,031	14,926	13,201	3,300	16,501	14,642	3,419	18,061
Renal system	32,336	13,792	46,128	35,197	14,042	49,239	38,115	14,425	52,540
Male reproduction system	217	449	666	223	466	689	272	479	751
Female reproduction system	240	480	720	278	457	735	337	521	858
Pregnancy	55	26	81	83	35	118	83	37	120
Hematologic system	2,706	126	2,832	2,836	126	2,962	3,093	106	3,199
Myeloproliferative system	948	217	1,165	977	204	1,181	1,010	230	1,240
Infection	16,160	4,407	20,567	16,553	4,087	20,640	16,791	4,166	20,957
Psychological disorders	4,010	235	4,245	4,359	221	4,580	4,307	204	4,511
Injury/poisoning	3,100	1,929	5,029	3,450	2,038	5,488	3,832	2,167	5,999
Burns	42	48	90	*	*	*	*	*	*
Other factors	8,464	792	9,256	10,493	907	11,400	11,578	955	12,533
Unclassified	*	2,655	2,655	*	3,453	3,453	*	3,708	3,708
HIV	1,461	142	1,603	1,636	165	1,801	1,895	183	2,078
All	245,576	117,766	363,342	269,434	122,917	392,351	288,486	127,187	415,673
PERITONEAL DIALYSIS									
Nervous system	2,235	241	2,476	1,981	207	2,188	1,855	231	2,086
Eye	23	31	54	23	29	52	23	19	42
Ear, nose, & throat	103	20	123	122	10	132	105	*	109
Respiratory system	1,953	94	2,047	1,850	86	1,936	1,697	97	1,794
Circulatory system	6,273	3,971	10,244	5,573	3,466	9,039	5,424	3,270	8,694
Gastrointestinal system	5,295	1,281	6,576	4,428	1,074	5,502	4,298	990	5,288
Hepatic system	653	275	928	504	246	750	525	241	766
Muscular/skeletal system	541	674	1,215	506	610	1,116	505	574	1,079
Skin/breast	395	219	614	390	207	597	424	235	659
Endocrine system	2,139	299	2,438	1,862	333	2,195	1,886	270	2,156
Renal system	2,933	1,228	4,161	2,555	1,139	3,694	2,586	1,114	3,700
Male reproduction system	38	46	84	27	43	70	23	39	62
Female reproduction system	39	92	131	39	63	102	38	67	105
Pregnancy	*	*	*	*	*	*	*	*	*
Hematologic system	379	*	388	350	*	358	343	10	353
Myeloproliferative system	49	*	58	58	*	63	69	20	89
Infection	1,585	379	1,964	1,233	313	1,546	1,136	286	1,422
Psychological disorders	356	20	376	267	27	294	269	*	277
Injury/poisoning	2,661	1,974	4,635	2,625	1,873	4,498	2,513	1,629	4,142
Burns	*	*	*	*	*	*	*	*	*
Other factors	914	65	979	899	65	964	955	81	1,036
Unclassified	*	346	346	*	396	396	*	388	388
HIV	151	17	168	151	14	165	126	14	140
All	28,722	11,295	40,017	25,449	10,217	35,666	24,805	9,589	34,394

One DRG per discharge.

*Values for cells with fewer than 10 discharges are excluded.

Table E.27 (continued)

Total Hospital Discharges: by General Diagnostic Related Group*period prevalent patients, 1998-2000 combined, by primary diagnosis & age; grouped by gender & race*

TRANSPLANT	1998			1999			2000		
	Medical	Procedure	All	Medical	Procedure	All	Medical	Procedure	All
Nervous system	1,868	319	2,187	1,886	282	2,168	2,114	319	2,433
Eye	41	51	92	48	46	94	62	35	97
Ear, nose, & throat	430	70	500	547	65	612	425	63	488
Respiratory system	3,076	239	3,315	3,600	264	3,864	3,575	275	3,850
Circulatory system	5,032	2,806	7,838	5,186	2,782	7,968	5,693	2,924	8,617
Gastrointestinal system	2,750	826	3,576	3,017	785	3,802	3,351	838	4,189
Hepatic system	1,041	485	1,526	1,081	492	1,573	1,172	570	1,742
Muscular/skeletal system	1,010	1,787	2,797	1,165	1,711	2,876	1,128	1,804	2,932
Skin/breast	1,118	414	1,532	1,150	418	1,568	1,261	429	1,690
Endocrine system	2,812	462	3,274	3,003	492	3,495	3,091	560	3,651
Renal system	7,278	2,484	9,762	7,707	2,593	10,300	8,407	2,669	11,076
Male reproduction system	62	99	161	67	120	187	74	139	213
Female reproduction system	85	212	297	64	205	269	84	240	324
Pregnancy	78	48	126	99	36	135	72	44	116
Hematologic system	472	38	510	494	40	534	603	56	659
Myeloproliferative system	208	70	278	178	92	270	223	84	307
Infection	2,513	451	2,964	2,542	412	2,954	2,491	401	2,892
Psychological disorders	448	*	453	491	*	494	547	*	552
Injury/poisoning	378	252	630	437	219	656	494	249	743
Burns	10	12	22	*	*	*	*	*	*
Other factors	930	43	973	1,079	57	1,136	1,111	70	1,181
Unclassified	*	351	351	*	495	495	*	528	528
HIV	*	*	*	*	*	*	*	*	*
All	31,648	11,524	43,172	33,847	11,609	45,456	35,978	12,302	48,280

One DRG per discharge.

*Values for cells with fewer than 10 discharges are excluded.

